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 Abstract 
 The advent of monoclonal antibody (mAb)-based anti-vascular endothelial 
growth factor (VEGF) therapy for treatment of wet age-related macular degeneration 
(AMD) has significantly improved the clinical outcomes in patients. However, monthly 
intravitreal injection of the anti-VEGF agents is inconvenient for patients and introduce 
the risks of infection, inflammation, and hemorrhage. Therefore, the development of 
intravitreal sustained release formulations of anti-VEGF agents would be beneficial to 
patients. The work in this dissertation investigated poly(lactic-co-glycolic acid) (PLGA) 
depot formulations to address this unmet need. 
 Active self-encapsulating PLGA microspheres with high molecular weight 
dextran sulfate (HDS) as a trapping agent and ZnCO3 as an antacid demonstrated 
continuous 8-week in vitro release of the immunoreactive bevacizumab Fab fragments, 
however, loading and encapsulation efficiency were low. Adjusting loading parameters 
(e.g., ZnCO3 and HDS content, loading buffer pH, and protein concentration in loading 
solution) did not significantly improve those values.  
 PLGA millicylindrical implants suitable for intravitreal injection were next 
employed as sustained release formulations of the anti-VEGF full-length mAb, 
bevacizumab. To stabilize the encapsulated mAb against the acidic microenvironment 
inside the PLGA implants during release period, MgCO3 was co-encapsulated. To 
prevent aggregation of bevacizumab during powder preparation, trehalose was co-
lyophilized with the mAb above a critical level. The presence of osmotically active 
 xviii 
 
excipients necessary to stabilize the mAb also caused a rapid uncontrolled release due to 
polymer swelling. To offset this effect, the lateral surface of implants was coated with 
pure PLGA. The optimized coated implants demonstrated continuous release kinetics in 
vitro over six weeks with high (>80%) total cumulative release. The released 
bevacizumab over this entire period retained > 90 % monomer content as well as 
excellent preservation of immunoreactivity and secondary structure.  
 Although there have been several attempts to develop sustained release 
formulations of the anti-VEGF mAbs, one or more desirable but unmet characteristics 
(biocompatibility of formulations, high loading (w/w) and loading efficiency, near zero-
order release kinetics with near complete release, and well-preserved stability of the 
released drugs) have hindered their clinical development. The data presented in this work 
provide a new paradigm for controlled release of stable bevacizumab from PLGA with 
the desired characteristics in various aspects, which both supports further development of 
this approach for wet AMD treatment and a generalizable application to site-specific 
controlled release of therapeutic mAbs. 
 1 
 
Chapter 1: Introduction 
 Therapeutic Monoclonal Antibody 
Since the end of the twentieth century, macromolecules such as nucleic acids and 
proteins have been emerging categories of therapeutics. In particular, therapeutic 
monoclonal antibodies have been developed and approved to the market since the 
hybridoma technique of Köhler and Milstein was introduced in 1975 [1]. Natural immune 
systems utilize antibodies to withstand the attacks of microorganism or foreign 
substances. Antibodies specifically bind to their antigens either on the cell surface or 
soluble substances and neutralize them. Natural antibodies against the same target 
molecules are ‘polyclonal’ antibodies which mean that they are a combination of 
antibody molecules produced against the same antigen, but typically target different 
epitopes on the antigen because different B cells produce different antibody molecules. 
Contrary to this, ‘monoclonal’ antibodies are produced from the same cell clones and are 
basically identical molecules which target the same antigen and the same epitope. The 
hybridoma technique enabled monoclonal antibodies to be produced synthetically in vitro 
by fusing myeloma cells with B cells. Since monoclonal antibodies bind to the target 
antigens quantitatively and they are homogeneous in terms of molecular identity, they 
can be developed as therapeutics [2] and monoclonal antibody therapy is defined as the 
use of monoclonal antibodies to neutralize specific target cells or proteins causing 
diseases. The indications of therapeutic monoclonal antibodies include several types of 
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cancer, immune disorders and viral infections. By 2014, more than forty antibody-based 
therapeutics including Fab fragments, and antibody-drug conjugates have been approved 
around the world and hundreds of monoclonal antibodies are undergoing clinical trials 
[3]. Most of them are concerned with immunological and oncological targets [4]. Table 
1.1 shows a recent list of antibody-based therapeutics approved in the US and Europe. 
 
Table 1.1: Marketed therapeutic monoclonal antibody-based products. Adapted from 
ref [3]. 
Brand name (INN) 
Original 
BLA/MAA 
Applicant 
Company 
Reporting US 
Sales 
Company 
Reporting EU 
Sales 
Year of 
First 
Approval 
2013 
Global 
Sales 
($M)a 
Abthrax 
(raxibacumab) 
Human Genome 
Sciences GlaxoSmithKline N/Ab 2012 23 
Actemra 
(tocilizumab) Roche Roche Roche 2009 1,119 
Adcetrisc 
(brentuximab 
vedotin) 
Seattle Genetics Seattle Genetics 
Takeda 
Pharmaceutical 
Co. 
2011 253 
AlprolIXd (Factor 
IX Fc fusion protein) Biogen Idec Biogen Idec N/A 2014 NoMe 
Arcalystf 
(rilonacept) 
Regeneron 
Pharmaceuticals 
Regeneron 
Pharmaceuticals N/A 2008 17 
Arzerra 
(ofatumumab) GlaxoSmithKline GlaxoSmithKline GlaxoSmithKline 2009 117 
Avastin 
(bevacizumab) Genentech Roche Roche 2004 6,748 
Benlysta 
(belimumab) 
Human Genome 
Sciences GlaxoSmithKline GlaxoSmithKline 2011 228 
Cimziag 
(certolizumab pegol) UCB UCB UCB 2008 789 
Cyramza 
(ramucirumab) Eli Lilly and Co. Eli Lilly and Co. N/A 2014 NoMe 
Eloctateh (Factor 
VIII Fc fusion 
protein) 
Biogen Idec Biogen Idec N/A 2014 NoMe 
Enbreli (etanercept) Immunex Amgen Pfizer 1998 8,325 
Entyvio 
(vedolizumab) 
Takeda 
Pharmaceuticals 
U.S.A., Inc 
Takeda 
Pharmaceutical 
Co. 
Takeda 
Pharmaceutical 
Co. 
2014 NoMe 
Erbitux (cetuximab) ImClone Systems Bristol-Myers Squibb Merck KGaA 2004 1,926 
Eyleaj (aflibercept) Regeneron Pharmaceuticals 
Regeneron 
Pharmaceuticals 
Bayer Healthcare 
Pharmaceuticals 2011 1,851 
Gazyva 
(obinutuzumab) Genentech Roche Roche 2013 3 
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Herceptin 
(trastuzumab) Genentech Roche Roche 1998 6,559 
Humira 
(adalimumab) 
Abbott 
Laboratories AbbVie AbbVie 2002 10,659 
Ilaris 
(canakinumab) 
Novartis 
Pharmaceuticals 
Novartis 
Pharmaceuticals 
Novartis 
Pharmaceuticals 2009 119 
Kadcylak (ado-
trastuzumab 
emtansine) 
Genentech Roche Roche 2013 252 
Keytruda 
(pembrolizumab) Merck & Co. Merck & Co. N/A 2014 NoMe 
Lemtrada 
(alemtuzumab) 
Genzyme 
Therapeutics N/A Sanofi 2013 3 
Lucentisl 
(ranibizumab) Genentech Roche 
Novartis 
Pharmaceuticals 2006 4,205 
Nplatem 
(romiplostim) Amgen Amgen Amgen 2008 427 
Nulojixn (belatacept) Bristol-Myers Squibb 
Bristol-Myers 
Squibb 
Bristol-Myers 
Squibb 2011 26 
Orenciao (abatacept) Bristol-Myers Squibb 
Bristol-Myers 
Squibb 
Bristol-Myers 
Squibb 2005 1,444 
Perjeta(pertuzumab) Genentech Roche Roche 2012 352 
Proliap (denosumab) Amgen Amgen GlaxoSmithKline 2011 824 
Remicade 
(infliximab) Centocor 
Johnson & 
Johnson Merck & Co. 1998 8,944 
Removabq 
(catumaxomab) 
Fresenius 
Biotech N/A 
NeoPharm 
Group 2009 5 
ReoPror (abciximab) Centocor Lilly N/A 1994 127 
Rituxan (rituximab) Genentech Roche Roche 1997 7,500 
Simponi/ 
Simponi Aria 
(golimumab) 
Centocor Ortho 
Biotech 
Johnson & 
Johnson Merck & Co. 2009 1,432 
Simulect 
(basiliximab) 
Novartis 
Pharmaceuticals 
Novartis 
Pharmaceuticals 
Novartis 
Pharmaceuticals 1998 30s 
Soliris (eculizumab) Alexion Pharmaceuticals 
Alexion 
Pharmaceuticals 
Alexion 
Pharmaceuticals 2007 1,551 
Stelara 
(ustekinumab) 
Janssen-Cilag 
International 
Johnson & 
Johnson 
Johnson & 
Johnson 2009 1,504 
Sylvant (siltuximab) Janssen Biotech Johnson & Johnson 
Johnson & 
Johnson 2014 NoMe 
Synagis 
(palivizumab) 
Abbott 
Laboratories AstraZeneca Abbvie 1998 1,887 
Tysabri 
(natalizumab) Biogen Idec Biogen Idec Biogen Idec 2004 1,527 
Vectibix 
(panitumumab) Amgen Amgen Amgen 2006 389 
Xgevap (denosumab) Amgen Amgen Amgen 2010 1,030 
Xolair (omalizumab) Genentech Roche Novartis 2003 1,465 
Yervoy (ipilimumab) Bristol-Myers Squibb 
Bristol-Myers 
Squibb 
Bristol-Myers 
Squibb 2011 960 
Zaltrapt (ziv-
aflibercept) Sanofi Aventis Sanofi Sanofi 2012 70 
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Zevalinu 
(ibritumomab 
tiuxetan) 
IDEC 
Pharmaceuticals 
Spectrum 
Pharmaceuticals 
Spectrum 
Pharmaceuticals 2002 29 
a Sales information obtained from company annual reports and other publically available sources. 
b N/A denote product not available in this region. 
c Antibody-Drug Conjugate, MMAE. 
d Fc Fusion Protein, Fc-Factor IX. 
e Product approval in 2014; no sales in 2013. 
f Fc Fusion Protein, Fc-IL1R. 
g Fab Conjugate, PEG (produced by microbial fermentation). 
h Fc Fusion Protein, Fc-Factor VIII. 
i Fc Fusion Protein, Fc-TNFR. 
j Fc Fusion Protein, Fc-VEGFR. 
k Antibody-Drug Conjugate, DM1. 
l Fab (produced by microbial fermentation). 
m Fc Fusion Protein, Fc-TPO-R binding peptide (produced by microbial fermentation). 
n Fc Fusion Protein, Fc-CTLA-4 with amino acid substitutions. 
o Fc Fusion Protein, Fc-CTLA-4. 
p Prolia and Xgeva are considered as two individual products even though they contain the same bulk monoclonal antibody. 
q Bispecific, Tri-functional Antibody. 
r Sales data not disclosed, small patient market, bioTRAK® estimate of global sales. 
s Fab, produced by papain digestion of full length monoclonal antibody. 
t Fc Fusion Protein, Fc-VEGFR. 
u Antibody Conjugate, Y-90. 
 
Since the beginning of the twenty-first century, the market for therapeutic 
monoclonal antibodies has grown exponentially. In 2015, therapeutic monoclonal 
antibody-based products occupied six spots among the ten best-selling drugs worldwide 
(Table 1.2) [5]. As a new era of personalized therapy emerges in modern medicine, the 
use of therapeutic monoclonal antibodies lies at the forefront, and much research in the 
broad therapeutic antibody field is still necessary. 
 
Table 1.2: Top ten drugs by sales. Adapted from ref [5]. 
Ranking Product Active Ingredient Main Therapeutic Indication Company 
2015 
Revenuea 
1 Humirab Adalimumab Immunology (Organ Transplant, Arthritis etc.) AbbVie 14,012 
2 Harvoni Ledipasvir and Sofosbuvir 
Infectious Diseases (HIV, 
Hepatitis etc.) Gilead Sciences 13,864 
3 Enbrelb Etanercept Immunology (Organ Transplant, Arthritis etc.) Amgen/ Pfizer 8,697 
4 Remicadeb Infliximab Immunology (Organ Transplant, Arthritis etc.) 
Johnson & 
Johnson/ Merck 8,355 
5 MabThera/Rituxanb Rituximab Oncology Roche 7,115 
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6 Lantus Insulin Glargine Diabetes Sanofi 7,029 
7 Avastinb Bevacizumab Oncology Roche 6,751 
8 Herceptinb Trastuzumab Oncology Roche 6,603 
9 Revlimid Lenalidomide Blood Related Disorders Celgene Corporation 5,801 
10 Sovaldi Sofosbuvir Infectious Diseases (HIV, Hepatitis etc.) Gilead Sciences 5,276 
a US$ in millions. 
b Therapeutic monoclonal antibody-based product. 
 
 
1.1.1 Production and characteristics of monoclonal antibodies 
In the late nineteenth century, Kitasato and Behring showed that the serum from 
human or horses recovered from an infectious disease can treat the same disease in 
another human patients or animals, which is called, ‘serum therapy’ [4]. Behring was 
awarded the Nobel Prize in Medicine and Physiology for discovery of the serum therapy 
in 1901. Early serum therapy utilized crude serum, thus it had a lot of side effects. Later, 
improved serum therapy using isolated natural antibodies from the immunized serum 
reduced some of the side effects. However, using isolated polyclonal antibodies from the 
serum of human or animals still had some drawbacks, which are inefficient 
manufacturing processes and inconsistent efficacy due to the undefined nature of 
polyclonal antibodies.  
After the hybridoma technique was introduced in 1975, most of the antibody 
therapies have utilized monoclonal antibodies. Hybridoma cells can produce monoclonal 
antibodies either in cell culture medium or in animal ascites after injection of the 
hybridoma cells into the peritoneal cavity, but production in cell culture is usually 
preferred due to ethical concerns [6]. After collecting a media from cell culture or ascites 
fluid, antibodies should be purified. For purification, several methods can be used, 
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including filtration, size exclusion chromatography, ion exchange chromatography, 
protein A/G affinity chromatography, and antigen affinity purification [7].    
Early therapeutic monoclonal antibodies were murine antibodies because natural 
murine spleen B cells were used to make hydridoma cells. But the difference between 
murine and human immune systems resulted in immunogenic issues of murine antibodies 
injected into human body. Murine antibodies have shorter half-lives than human 
antibodies in human plasma and elicit immunogenic response, thus potentially 
endangering patients. To overcome these problems, chimeric and humanized monoclonal 
antibodies were later developed using recombinant DNA technology (Figure 1.1). 
Chimeric antibodies consist of murine variable regions and human constant regions, thus 
making them less immunogenic in human and increasing serum half-life. Humanized 
antibodies were also developed by grafting ‘complementarity-determining regions 
(CDRs)’ into the human antibody framework, thus making them even less immunogenic. 
Initially, the binding affinity of humanized antibodies was weaker than the original 
murine antibodies. Therefore, mutation in the CDR using recombinant techniques was 
introduced to increase the binding affinity of humanized antibodies [4]. Now, human 
monoclonal antibodies can also be produced using transgenic mice or phage display 
libraries [8].   
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Figure 1.1: Schematic diagrams describing murine, chimeric, humanized and human 
antibodies. From ref [9]. 
 
1.1.2 Stability of monoclonal antibodies  
 Physicochemical and biological stability of monoclonal antibodies has been an 
important issue for clinical development and overcoming this issue should be an 
important goal to produce a final product. Physicochemical stability of antibodies can be 
viewed as a combination of ‘conformational’ stability and ‘colloidal’ stability [10]. 
Conformational stability refers thermodynamic stability of antibodies, which is about 
how the native antibodies are unfolded and refolded and it can be influenced by pH, ionic 
strength, and temperature. Colloidal stability of antibodies reflects how stable antibody 
molecules are when interacting with each other. Conformational and colloidal 
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instabilities of antibodies cause aggregation which is one of the most critical concerns in 
developing therapeutic monoclonal antibody products since antibody molecules have a 
propensity to aggregate easily [11]. Conformational and colloidal stabilities cannot be 
considered separately and should influence each other.  
The instabilities during manufacturing and storage can be enhanced by antibody 
engineering and controlling pH, temperature, physical stress, concentration and 
excipients [10]. Temperature and pH during manufacturing and storage can be easily 
controlled. However, physical stress such as agitation cannot be completely avoided 
during manufacturing and storage and is one of the major factors inducing aggregation of 
antibodies, so it is a major hurdle for the development of therapeutic monoclonal 
antibody products. There has been some research to prevent agitation-induced 
aggregation of antibodies using protein A or G, peptides [12] or cyclodextrin [13]. High 
concentrations of antibodies in formulations are also needed since some methods of 
administration can accommodate limited volume of injection, but high concentration 
often accelerates aggregation of antibodies. To prevent aggregation of antibodies in 
formulations, surfactants such as polysorbates are commonly used in antibody 
formulations, but they cannot prevent aggregation completely [14]. Another common 
excipient to improve stability of antibodies in formulations is sugars or sugar alcohols 
such as trehalose, sucrose, sorbitol and mannitol [15]. Three theories have been proposed 
as stabilizing mechanisms of sugars for proteins: vitrification, preferential exclusion and 
water replacement theories [16–18]. Vitrification theory proposes the physical 
entrapment of protein in the glassy sugar matrix, thus the entrapped proteins have 
restricted mobility which inhibits unfolding and denaturation under stress condition. In 
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preferential exclusion theory, sugar does not interact directly with protein. Instead, they 
compete for the formation of hydrogen bonds with water molecules. Trehalose is 
especially known to interact with water molecules strongly, thus reducing available water 
molecules to interact with the protein. By this, the hydration radius of protein decreases, 
resulting in compactness and rigidity of the protein and increased stability. On the other 
hand, water molecules play a key role in maintaining the three-dimensional structure of 
proteins in aqueous solution through hydrogen bonds with the hydrophilic residues of 
proteins. Therefore, loss of water molecules during lyophilization can collapse the three-
dimensional structure and decrease protein stability. In water replacement theory, 
abundant hydroxyl groups in sugar molecules are thought to interact with proteins in the 
solid state through hydrogen bonds and effectively replace water molecules to stabilize 
the protein structure. Figure 1.2 simply describes the stabilizing mechanism of the three 
theories. 
 
Figure 1.2: Various theories to explain the stabilizing mechanism of sugar for protein. 
Modified from ref [17]. 
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 Wet Age-related Macular Degeneration 
Age-related macular degeneration (AMD) is a condition in which the macula (the 
center of retina) is displaced from its normal position due to drusen, geographic atrophy, 
choroidal neovascularization, or disciform scar formation, resulting in decreased or blurry 
vision and finally central vision loss in patients aged 50 years and older [19–21]. The 
prevalence of AMD in people aged 50 years and older in the United states is 9.2 % and it 
is the main cause of vision loss [19]. There are two forms of AMD, which are dry and 
wet. In the dry form of AMD, the degeneration of the retina is associated with the 
formation of small yellow or white accumulations of extracellular material, known as 
drusen, under the macula. Currently, there is no effective treatment for this form of AMD 
[22]. Although dry AMD accounts for 90 % of AMD, the wet form is responsible for 
90 % of severe vision loss from AMD [19,20]. In wet AMD, abnormal blood vessels 
grow under the retina and macula, which is known as choroidal neovascularization 
(CNV). Then, the new blood vessels may bleed or leak fluid, and cause the macula to 
bulge or lift up from its normal position, thus resulting in the distortion or loss of central 
vision. There have been three types of treatments to limit or delay loss of vision in 
patients: laser photocoagulation, photodynamic therapy, and anti-vascular endothelial 
growth factor (VEGF) therapy. Laser photocoagulation is a type of laser surgery that uses 
an intense argon laser to burn small areas of the retina and the abnormal blood vessels 
under the macula. The burns seal the blood vessels by forming scar tissue, thus 
preventing them from leaking fluid under the macula. Photodynamic therapy (PDT) 
utilizes an intravascular photosensitizer, verteporfin, and low energy visible red laser to 
seal the leaking. This “cold laser” activates verteporfin flowing through the blood vessels 
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under the macula, creating highly reactive singlet oxygen which directly damages the 
endothelial cells of the abnormal blood vessels. However, these two treatment options for 
wet AMD represent only a palliative therapy since they temporarily seal the existing 
leaky blood vessels, but do not prevent the growth of new abnormal vessels [23]. Since 
2004, the advent of anti-VEGF therapies has efficiently slowed vision loss and even 
improved visual acuity in wet AMD patients [24]. 
1.2.1 Anti-VEGF therapy 
In wet AMD, the overexpression of VEGF stimulates the growth of abnormal 
blood vessels under the retina. Therefore, anti-VEGF agents have been developed to treat 
wet AMD by neutralizing VEGF activity. The first FDA-approved anti-VEGF agent in 
2004 was Macugen® (pegaptanib, anti-VEGF aptamer) which demonstrated better 
outcomes than the conventional treatment such as laser coagulation or PDT did, however 
it did not improve visual acuity in patients [24]. The second FDA-approved anti-VEGF 
agent for wet AMD was Lucentis® (ranibizumab, anti-VEGF monoclonal antibody Fab 
fragment), which was, until recently, leading the market for wet AMD treatment since it 
was able to improve visual acuity significantly in patients [25]. On the other hand, 
Avastin® (bevacizumab, anti-VEGF whole monoclonal antibody) has been extensively 
used off-label by physicians although it is only officially FDA-approved for certain types 
of cancer, since a single dose of it for wet AMD costs only one-fortieth of that of 
Lucentis® while it demonstrates similar efficacy to Lucentis® [26,27]. The recently FDA-
approved Eylea® (aflibercept, a recombinant fusion protein of human VEGF receptors 1 
and 2 extracellular domains and a Fc portion of human IgG1) for wet AMD in 2011 is 
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currently the leading anti-VEGF agent product since it showed better outcomes than the 
other anti-VEGF agents [28].  
1.2.2 Need for sustained release formulations 
The anti-VEGF antibodies are administered monthly by intravitreal injection, but 
the dosing regimen is very inconvenient for patients [29] and repeated injections into the 
eye may induce infection, inflammation and hemorrhage [30]. Therefore, developing 
sustained release formulations of the anti-VEGF agents is needed to reduce their 
administration frequency for improved patient compliance and convenience and 
minimize the complications. It is important for drugs to maintain the concentration in the 
therapeutic window in the target sites for high efficacy and low toxicity. Sustained 
release formulations can help maintain the optimal concentrations of the anti-VEGF 
antibodies in the therapeutic window for a long period with minimal instability. 
 
 Poly(lactic-co-glycolic acid) Depots for Controlled Release 
Poly(lactic-co-glycolic acid) (PLGA) is a copolymer which is synthesized from 
two different monomers, lactic acid and glycolic acid (Figure 1.3) [31]. PLGA has been 
used in numerous FDA-approved therapeutic devices since the polymer is biodegradable 
and biocompatible [32–35]. Therefore, there has been a large body of research utilizing 
PLGA as a component of drug delivery systems. The shapes of PLGA formulations are 
diverse, and range from microspheres, nanoparticles, implants, and films [36–39]. Factors 
such as molecular weight, hydrophilicity, and crystallinity influence the rate of 
degradation of PLGA and subsequently the release of the drug. Generally, more 
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hydrophilic PLGA with lower molecular weight degrades faster and since glycolic acid is 
more hydrophilic than lactic acid, therefore, PLGA with more glycolic acid degrades 
faster [40]. However, the exception to this rule is that PLGA with 50:50 (lactic 
acid:glycolic acid) ratio shows the fastest degradation rate because increasing glycolic 
acid content above 50 % results in crystallinity in the polymer. PLGA with more 
amorphous nature degrades faster as crystallites limit water penetration and polymer 
mobility [41]. 
 
Figure 1.3: Structure of poly(lactic-co-glycolic acid). n= number of units of lactic acid; 
m= number of units of glycolic acid. Modified from ref [31]. 
 
1.3.1 Active self-encapsulating PLGA microspheres 
Encapsulation of drugs into PLGA microspheres can be achieved by a number of 
methods, such as spray drying, coacervation, and emulsion-based methods [42]. Among 
these preparing methods, the emulsion-solvent evaporation method is the most common 
and suitable for encapsulation of therapeutic monoclonal antibodies because the other 
two methods have some drawbacks. Spray drying requires high temperature to remove 
the organic solvent, which is not good for antibody stability and some agglomeration of 
microspheres can also occur affecting product performance. Microspheres prepared by 
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coacervation may have residual toxic solvents, coacervating agents, and hardening agents 
[43].  
To encapsulate monoclonal antibodies into PLGA microspheres, double emulsion 
method, water-in-oil-in-water (W/O/W) is preferred rather than single emulsion methods 
such as oil-in-water (O/W), oil-in-oil (O/O), and solid-in-oil-in-water (S/O/W) since 
W/O/W emulsion is the most suitable for encapsulation of hydrophilic antibodies [44]. 
Briefly describing the procedure, the inner water phase which dissolves antibodies is 
added to organic solvent, such as methylene chloride, dissolving PLGA and 
homogenized, to create the first emulsion. Immediately, this first emulsion is added into 
the bulk outer water phase and vortexed, thus creating double emulsions. This method 
can encapsulate large amount of antibody inside the microspheres. However, this also has 
drawbacks, which are instability of antibodies due to the interface of water and organic 
solvent and micronization force, and difficulty of sterilization of microspheres because 
they already have antibodies inside themselves and the process of sterilization may harm 
the activity of antibodies. To overcome these limitations, the “active self-encapsulating” 
method was developed in the Schwendeman laboratory [44,45]. In this method, the 
antibodies can be loaded into the already-prepared drug-free PLGA microspheres 
containing a trapping agent in the interconnected pores, and avoid stresses during the 
preparation of microspheres. The role of the trapping agent is to entrap the antibody from 
the outside solution by maintaining a concentration gradient from outside to inside 
microspheres. The first example of such a trapping agent that was used was Al(OH)3 gel, 
which binds to protein antigens with high efficiency [45]. By ’self-encapsulating’, there 
is no chance for antibody molecules to make contact with organic solvent and 
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sterilization of the particles can be performed before loading of antibodies, thus be less 
damaging to the proteins overall. Figure 1.4 describes the advantages of this new 
encapsulation technology over the traditional double emulsion method. PLGA 
microspheres prepared by W/O/W double emulsion method are porous, thus providing 
large inner space for active loading of antibodies. However, this large surface created by 
the pore network also could potentially induce undesired fast release of encapsulated 
drugs. Pore closing of PLGA microspheres solves this problem. The mechanism of pore 
closing applied by the Schwendeman laboratory is based on passive polymer healing after 
incubating the microspheres above the glass transition temperature (Tg) of PLGA. Above 
the Tg, PLGA polymers become mobile and rearrange, therefore, pores are closed 
spontaneously to achieve minimal surface energy. After, the pore-closed PLGA 
microspheres can release the encapsulated drugs in a sustained manner. Hereafter, the 
phrase, ‘active self-encapsulation’ will refer to the concept combining ‘active loading’ 
and ‘pore closing.’ 
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Figure 1.4: Comparison of traditional vs. self-encapsulating PLGA microspheres. 
From ref [44]. 
 
 17 
 
1.3.2 PLGA millicylindrical implants 
PLGA millicylindrical implant (or simply PLGA implant) is another common 
form of PLGA depot formulations which can be employed for sustained release of the 
antibodies. Loading of drugs into PLGA implants is simply achieved by suspending drug 
powders in the PLGA/acetone solution, therefore the loading efficiency is theoretically 
100 %, and it is easy to control loading of drugs [38,46]. There has been an FDA-
approved, intravitreally injectable PLGA implant for controlled release of 
dexamethasone, Ozurdex® [47], providing a clinical precedent for use of PLGA implants 
in the eye. The administration of this implant is accomplished by intravitreal injection via 
a special applicator without any surgical procedures. The use of anhydrous 
microencapsulation when preparing PLGA millicylindrical implants similar to Ozurdex® 
was additionally developed by the Schwendeman group in order to eliminate the stress 
from organic solvent/water interface as occurs during common methods of protein 
encapsulation [38,46,48]. 
 
 Current Strategies for Sustained Delivery of Anti-VEGF Agents 
In order to reduce administration frequency for improved compliance and 
convenience of wet AMD patients, multiple strategies for sustained delivery of the anti-
VEGF agents have been suggested, ranging from biodegradable polymeric depots to non-
degradable reservoir systems.  
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1.4.1 Biodegradable polymer-based depot formulations 
Anti-VEGF antibodies (bevacizumab or ranibizumab) have been encapsulated in 
PLGA-based depot formulations for sustained delivery. Li et al. reported that 
bevacizumab-encapsulating PLGA spheres of which the size ranged from 0.2 to 3 µm 
continuously released bevacizumab in vitro over 91 days without high initial burst release 
[49]. However, the loading (w/w) of bevacizumab in the well-formed spheres was only 
1.6 % and the total cumulative release was only 47 %. When the loading was increased to 
13 %, the particles no longer showed shape uniformity. Yandrapu et al. developed 
bevacizumab-encapsulating polylactic acid (PLA) nanoparticles in porous PLGA 
microparticles (NPinPMP) prepared by supercritical infusion and pressure quench 
technology [50]. By the technology, they achieved organic solvent-free encapsulation and 
continuous release of the antibodies for 4 months in vitro which was not achieved when 
the proteins were encapsulated directly in PLGA microparticles without PLA 
nanoparticles. The released bevacizumab from the NPinPMP showed high stability in 
various aspects, which was analyzed by size-exclusion chromatography (SEC), 
fluorescence spectroscopy, circular dichroism spectroscopy (CD), sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE), and enzyme-linked immunosorbent 
assay (ELISA). They also demonstrated longer residence times of bevacizumab 
encapsulated in the NPinPMP compared to free bevacizumab in a rat model. But, the 
limitation of this formulation was low loading (<1 %). On the other hand, to stabilize the 
antibodies during emulsification which is a common step to prepare PLGA particulate 
formulations, albumin was co-encapsulated [51,52]. By co-encapsulating albumin, they 
replaced the organic solvent/water interfaces which are deleterious for protein stability, 
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thus stabilizing bevacizumab. However, the aggregated albumin instead of bevacizumab 
could be problematic because protein aggregates are immunogenic [53]. 
Biodegradable polymers other than PLGA have also been utilized for sustained 
delivery of the anti-VEGF agents. Despite the several attempts, only a few of them, e.g. 
silk hydrogels [54], nanoporous thin film of polycaprolactone [55], poly(ethylene glycol)-
poly- (serinol hexamethylene urethane) reverse thermal gel [56,57], and pentablock 
copolymer nanoparticles [58], have achieved long duration (3-4 months) of release to be 
advantageous over the current dosing interval of the anti-VEGF agents. Although these 
previous researches with novel polymers were successful to extend the duration of 
release, more thorough evaluations of biocompatibility of the polymers and stability of 
the released proteins are needed for clinical development. 
1.4.2 Port delivery system 
The port delivery system (PDS), which was initially developed by ForSight 
Vision4 and licensed by Genentech for delivery of ranibizumab, is a refillable, non-
biodegradable implant designed to provide sustained release of ranibizumab into the 
vitreous for treatment of wet AMD (Figure 1.5) [59]. The ranibizumab-preloaded implant 
is inserted in the pars plana beneath the conjunctiva via the 3.2-mm scleral incision using 
standard retinal surgical procedures and sutures are not needed to close. The surgical 
procedure usually takes less than 15 minutes. After the initial implantation, ranibizumab 
can be refilled through the subconjunctival refill port in the office as needed. The device 
provides continuous release of ranibizumab into the vitreous between refill procedures. 
ForSight Vision4 has successfully completed a phase 1 clinical trial I in which most of 
the observed adverse effects were mild and transient in nature and the approximate visual 
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acuity gain was 15 letters at month 12 with the average refills of 4.2 in 18 efficacy-
evaluable study subjects. Genentech initiated a phase 2 clinical trial in 2015. 
 
Figure 1.5: The ranibizumab port delivery system. From ref [59]. 
 
1.4.3 NT-503 ECT implant 
Encapsulated cell technology (ECT) which has been licensed by Neurotech is a 
genetically engineered ocular implant that enables continuous production of therapeutic 
proteins from the encapsulated therapeutic cells in a non-biodegradable implant to the eye 
for over 2 years [60]. The ECT platform is based on the customized cell line which is 
immortalized, non-tumorigenic, and derived from normal human retinal pigment 
epithelial cells. NT-503, in which cells have been engineered to continuously produce a 
soluble VEGF receptor (sVEGFR) fusion protein, has been developed for the treatment 
of wet AMD and other neovascular diseases of the retina. Through a semipermeable 
membrane of the implant, inward diffusion of oxygen and nutrients for the cell survival 
and outward diffusion of the sVEGFR fusion protein for treatment of wet AMD are 
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enabled. Immune cells and host antibodies cannot permeate through the membrane, so the 
encapsulated cells are protected from the immune system. The NT-503 ECT implant has 
completed a phase 1 clinical trial, but the phase 2 clinical trial has been discontinued due 
to a larger than anticipated number of patients requiring rescue medication in the 
treatment arm. 
 
 Thesis Scope Overview 
In this dissertation, PLGA depot formulations of the anti-VEGF antibodies for 
treatment of wet AMD were evaluated. The overall objective of this work is to achieve 
high w/w loading and loading efficiency, and near zero-order, and complete release for 1-
3 months or longer with minimal instabilities of the antibodies by formulating them as 
PLGA controlled release depots. 
Chapter 2 of this work evaluates the active self-encapsulating PLGA 
microspheres previously developed in our lab as a depot formulation for the antibodies. 
High molecular weight dextran sulfate (HDS) and ZnCO3 were investigated as a trapping 
agent and an antacid, respectively. Various factors including HDS and ZnCO3 contents, 
loading buffer pH, and protein concentration in loading solution were studied to increase 
w/w loading and encapsulation efficiency. 
Chapter 3 investigates PLGA millicylindrical implants for sustained release of 
bevacizumab. In this chapter, trehalose was found to stabilize the antibodies against 
aggregation during powder preparation and an optimal ratio of trehalose and 
bevacizumab was sought to reduce the release rate of bevacizumab while maintaining its 
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anti-aggregating ability. This chapter also demonstrates how loading of total drug powder 
affects release kinetics of the antibodies. 
Chapter 4 further improves the PLGA implants from Chapter 3 by coating the 
lateral side of the implants with pure PLGA. Different PLGA concentrations for coating 
were tested and the stabilities of the released bevacizumab from the optimized coated 
implants were analyzed in various aspects. Confocal microscopy observed the release of 
proteins through the lateral side of coated implants. 
Chapter 5 emphasizes the key conclusions of this dissertation and discusses the 
future work to improve the PLGA depot formulations for clinical development. 
There is an appendix briefly describing preliminary work to develop a sustained 
release PLGA depot formulation of adeno-associated viruses (AAV) for improved gene 
therapy, which has a potential to improve long-term transduction and reduce the dose of 
AAV administration for reducing immune response.  
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Chapter 2: Active self-encapsulating PLGA microspheres of 
bevacizumab and its Fab fragments 
 Abstract 
In order to develop active self-encapsulating poly(lactic-co-glycolic acid) (PLGA) 
microspheres for controlled release of the anti-vascular endothelial growth factor (VEGF) 
antibodies, several candidates of trapping agents have been investigated. Enzymatically 
produced Fab fragments from bevacizumab were used as a model to mimic ranibizumab 
(Lucentis®) and to circumvent agitation-induced aggregation which commonly occurs 
with whole antibody molecules. The first trapping agent tested was Ca-alginate, a natural 
biopolymer found in brown algae, and is biocompatible, biodegradable and has negative 
charges for binding of the positively charged antibodies at loading pH of 5.5. Both 
loading and encapsulation efficiency were 2.8-4.0 % and 56.6-82.4 %, but the initial burst 
release on day 1 was ~60 % and the release stopped afterwards. Next, high molecular 
weight dextran sulfate (HDS), another negatively charged biopolymer, was tested as a 
trapping agent and has been successfully employed for encapsulating lysozyme and 
VEGF. In addition, ZnCO3 was encapsulated in the HDS-PLGA microspheres as an 
antacid to stabilize the encapsulated proteins. The formulation resulted in continuous and 
complete release of the immunoreactive anti-VEGF Fab fragments, however, loading and 
encapsulation efficiency would require further optimization. Subsequently, other anionic 
polymers were screened and poly(acrylic acid) (PAA) was chosen to be encapsulated in 
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PLGA microspheres as a trapping agent, however both loading and encapsulation 
efficiency were at undesired levels. Active self-encapsulating PLGA microspheres have 
served as successful formulations for controlled release of varying drugs, and here we 
have demonstrated the feasibility to use this strategy to encapsulate and stabilize anti-
VEGF antibodies. Further efforts to bolster the loading and improve the release profiles 
are warranted for clinical viability. 
 
 Introduction 
Wet age-related macular degeneration (wet AMD) is a severe form which is 
responsible for approximately 90 % of cases of severe vision loss due to AMD [1]. 
Overexpression of VEGF leads to abnormal growth of blood vessels under the macula, 
thus resulting in central vision loss. Therefore, anti-VEGF therapies were developed to 
treat wet AMD by neutralizing the overexpressed VEGF [2]. The current dosing schedule 
of anti-VEGF agents for treatment of wet AMD is monthly intravitreal injection, but this 
is very inconvenient for patients [3] and may induce infection, inflammation, and 
hemorrhage [4]. Here is a need for controlled release depots for the drugs which can 
reduce the administration frequency and improve patient comfort. 
PLGA microspheres have been extensively researched and used in several FDA-
approved products as depot systems of protein therapeutics for controlled release [5–7]. 
Although PLGA depots exhibit desirable qualities such as biodegradability and 
biocompatibility [8], a major drawback of conventional PLGA microspheres for protein 
drugs is the destabilization of proteins during encapsulation, sterilization, and release [9–
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12]. A common method of protein encapsulation in PLGA microspheres is the double 
emulsion-solvent evaporation method. In this process, proteins necessarily encounter 
deleterious conditions such as aqueous/organic interfaces, shear stress by micronization, 
and gamma radiation for sterilization. To bypass these stress factors, self-encapsulation 
technology has been developed, previously in our lab  [10]. By this new method, proteins 
can be loaded into pre-formed porous PLGA microspheres from an aqueous solution, 
thus avoiding all the above stressors. Through this method, drugs can be encapsulated by 
either passive or active loading. Passive loading utilizes a concentration gradient as a 
driving force to encapsulate the drug, however this method requires large quantities or 
high concentrations of protein and is inefficient. To overcome this, an active loading 
method was developed, which employs a trapping agent with binding affinity for the 
drugs to be encapsulated. This binding results in more partition of drugs inside the 
microspheres [10,11,13]. Proteins in PLGA matrix can also be destabilized due to the low 
microenvironmental pH created by acid byproducts from the polymer degradation during 
release. To neutralize the acidic pH in the microenvironment during the release, poorly 
soluble basic salts have been incorporated [9,14]. Lastly, in the hope of slowing down the 
release, surface pores were closed by incubating the microspheres at above the glass 
transition temperature [10,11]. The schematics of these processes were briefly described 
in Figure 2.1. 
In this chapter, we tested the hypothesis that active self-encapsulating PLGA 
microspheres can serve as controlled release depots for bevacizumab or its Fab 
fragments. Enzymatically produced Fab fragments from the whole antibodies of 
bevacizumab were also used to mimic the officially approved anti-VEGF Fab fragment, 
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ranibizumab (Lucenits®), the cost of which is significantly more expensive than the 
corresponding dose of bevacizumab (Avastin®) [15]. Bevacizumab and its Fab fragment 
are positively charged at neutral pH, so anionic polymers were incorporated in PLGA 
microspheres as a trapping agent to utilize an electrostatic interaction as a binding force. 
Poorly soluble basic salts were co-encapsulated in the polymer to provide continuous 
neutralization of the produced acids from polymer degradation [9]. Due to the limit of 
injection volume into the target site, both the w/w loading of the drug (>5 %), and 
encapsulation efficiency needs to be to be high. To develop formulations, the effects of 
basic salts and trapping agent content in microspheres, loading pH and concentration of 
the proteins in loading solution were tested. 
 
 Materials and Methods 
2.3.1 Materials 
Avastin® (bevacizumab) was purchased from the Central Pharmacy of the 
University of Michigan Hospital. PLGA 50:50 (inherent viscosity = 0.64 dL/g and Mw = 
54.3 kDa, ester terminated) was purchased from LACTEL Absorbable Polymers 
(Birmingham, AL). Recombinant human vascular endothelial growth factor (VEGF) was 
a generous gift from Genentech. All other reagents and supplies were purchased from 
commercial suppliers and were of analytical grade. 
2.3.2 Production of Fab fragments from bevacizumab 
Fab fragments of bevacizumab were produced by papain-digestion using a 
commercial Pierce™ Fab Preparation Kit (Thermo Fisher Scientific, MA). Briefly, the 
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whole antibodies were digested into their Fab and Fc fragments by immobilized papain 
resins for 6 h with an end-over-end mixer at 37°C. The resulting proteins were incubated 
with immobilized protein A columns. By spinning down the protein A columns, only Fab 
fragments were eluted as undigested antibodies and Fc fragments were bound to 
immobilized protein A. The bound proteins were eluted separately using elution buffer. 
2.3.3 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
Papain-digested bevacizumabs were analyzed by SDS-PAGE. The antibodies 
were digested by papain for 2 and 6 h to observe time dependency. Non-reduced and 
reduced proteins by boiling for 5 min at 95°C in the presence of 2-mercaptoethanol were 
mixed with sample loading buffer (Bio-Rad, CA) and run on Invitrogen PowerEase 500 
at 200 V for 30 min in polyacrylamide gel. Precision Plus Protein™ Unstained Standards 
(Bio-Rad) were used as molecular weight standard markers. The gel was stained by 
Coomassie blue dye. 
2.3.4 Protein quantification 
Protein quantification was performed using either bicinchoninic acid (BCA) 
assay, size-exclusion high-performance liquid chromatography (SE-HPLC) or size-
exclusion ultra-performance liquid chromatography (SE-UPLC) as described below. 
2.3.4.1 BCA assay 
Protein was quantified by Pierce™ BCA Protein Assay Kit (Thermo Fisher 
Scientific) according to manufacturer’s instruction. Protein samples and standards of 
known concentration in triplicate were added in a 96-well plate. The mixture of BCA 
reagent A and B at the ratio of 50:1 was added into each well. The plates were incubated 
at 37°C for 30 min and read using a plate reader (BioTek, VT) at 595 nm.  
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2.3.4.2 SE-HPLC & SE-UPLC 
The condition of SE-HPLC to quantify whole antibodies and Fab fragments of 
bevacizumab was followed as previously described [16] with slight modifications. The 
mobile phase (0.182 M KH2PO4, 0.018 M K2HPO4, and 0.25 M KCl, pH 6.2) was run at 
a flow rate of 0.5 mL/min through a column (TSK-GEL G3000SWxl; Tosoh Bioscience, 
Japan), and elution was monitored at 280 nm. The volume of injection was 50 µL, and 
the running time was 30 minutes. To quantify Fab fragments of bevacizumab, SE-UPLC 
was also performed using a ACQUITY UPLC BEH125 SEC column (Waters, MA) with 
the same mobile phase as in SE-HPLC at 0.3 mL/min. The volume of injection was 5 µL, 
and the running time was 11 min. The peaks were analyzed at 280 nm. All samples for 
SE-HPLC and SE-UPLC were filtered through 0.45 µm protein low binding filter. 
2.3.5 Determination of binding ratio of antibodies and trapping agents 
Aqueous solutions of trapping agents (high molecular weight (~500 kDa) dextran 
sulfate (HDS), poly acrylic acid (PAA), poly methacrylic acid (PMAA), poly 
styrenesulfonic acid (PSSA), pectin and carrageenan) were mixed with bevacizumab or 
its Fab fragment at different mass ratios in 10 mM histidine buffer, pH 5.5 at room 
temperature. After 1 h of incubation, the complex was centrifuged and unbound free 
protein in the supernatant was quantified by SE-HPLC. 
2.3.6 Preparation of active self-encapsulating PLGA microspheres 
Porous self-encapsulating PLGA microspheres were prepared using a water in-oil-in- 
water (w/o/w) double emulsion method. Two hundred to five hundred μL of inner water 
phase with varying amounts of trapping agents and D-trehalose in ddH2O (w/o/w) was 
homogenized into the oil phase, 200 or 250 mg/mL of PLGA in methylene chloride with 3 % 
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MgCO3 w/w (weight by weight of total microspheres) or 3-6 % ZnCO3 for 60 s at 17,000 rpm 
over an ice bath using the Tempest IQ homogenizer (Virtis, USA). To this first emulsion, 2 
mL of 5 % (w/v) PVA solution was immediately added and the mixture was vortexed at 70 % 
intensity for 60 s to create a double emulsion. The double emulsion was quickly poured into 
100 mL of 0.5 % (w/v) PVA solution and stirred for 3h in a fume hood at room temperature 
to form hardened microspheres. Hardened microspheres were than sieved (20-45, 45-90 μm) 
for collection and subsequently washed with ddH2O, lyophilized and stored at -20°C for 
future use. 
2.3.7 Active self-encapsulation of antibodies in PLGA microspheres 
Active self-encapsulation in porous PLGA microspheres consists of two 
subsequent steps: the first step is “loading” of the proteins in porous PLGA microspheres 
and the second step is “pore closing” of the surface of microspheres by incubating at 
above the glass transition temperature of the polymer. For loading, the porous PLGA 
microspheres were incubated in a protein solution of varying concentrations in 10 mM 
histidine buffer (pH 5.5) at 4°C or 25°C for 24 h on an orbital shaker with 320 rpm. 
Subsequently, the pore closing was carried out by incubating the microspheres at 43°C 
for 48 h which is well above the hydrated glass transition temperature of the polymer. 
The resulting particles were centrifuged and the supernatant was collected to measure 
loaded proteins by subtracting the remaining mass of proteins in the supernatant from the 
initial mass of proteins in loading solution. The w/w loading and encapsulation efficiency 
(EE) were calculated by the following equations: 
ݓ/ݓ	݈݋ܽ݀݅݊݃	 ൌ 	ܯܽݏݏ	݋݂	݈݋ܽ݀݁݀	݌ݎ݋ݐ݁݅݊ݏ	݅݊	݉݅ܿݎ݋ݏ݌݄݁ݎ݁ݏܶ݋ݐ݈ܽ	݉ܽݏݏ	݋݂	݉݅ܿݎ݋ݏ݌݄݁ݎ݁ݏ 	ൈ 100	% 
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ܧ݊ܿܽ݌ݏݑ݈ܽݐ݅݋݊	݂݂݁݅ܿ݅݁݊ܿݕ	 ൌ 	 ܯܽݏݏ	݋݂	݈݋ܽ݀݁݀	݌ݎ݋ݐ݁݅݊ݏ	݅݊	݉݅ܿݎ݋ݏ݌݄݁ݎ݁ݏܫ݊݅ݐ݈݅ܽ	݉ܽݏݏ	݋݂	݌ݎ݋ݐ݁݅݊ݏ	݅݊	݈݋ܽ݀݅݊݃	ݏ݋݈ݑݐ݅݋݊ 	ൈ 100	% 
 
The mass of proteins was measured as described in the above section, “protein 
quantification.” 
2.3.8 In vitro release study 
In vitro release kinetics was determined by suspending 5 - 20 mg of loaded 
microspheres in either PBST (phosphate buffered saline containing 0.02 % Tween 80 
w/w) pH 7.4 or PBST containing 1 % BSA (bovine serum albumin) used for enzyme 
linked immunosorbent assay (ELISA) assay. The concentration of particles in the release 
buffer ranged from 3 to 10 mg/mL. The particles were incubated in a 37°C incubator, at 
select time points were centrifuged at 8000 rpm for 5 min, and the supernatants were 
collected and replaced with the same volume of fresh release buffer. The protein content 
in the release supernatant collected from each time point was assayed to determine the 
release.  
2.3.9 Determination of immunoreactivity by ELISA 
ELISA was performed to determine immunoreactive activity of Fab fragments 
and whole antibodies of bevacizumab as described previously [17] with some 
modifications. Briefly, 96-well ELISA microplates were pre-coated with 50 μl of VEGF 
(0.5 μg/mL) solution in PBS (phosphate buffered saline, pH 7.4) at 4°C overnight. After 
washing with 350 μl of PBS four times, 100 μl of PBS containing 1 % BSA was added 
for blocking and incubated at room temperature for 2 h. After washing, 50 μl of Fab 
fragment standards (0 ~ 800 ng/mL) or bevacizumab whole antibody standards (0 ~ 2560 
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ng/mL) and samples diluted in PBST containing 1 % BSA were added into each well and 
incubated at room temperature for 1 h. After washing, 50 μl of secondary antibody 
(alkaline phosphatase conjugated goat anti-human IgG, Fab specific) was added at 1: 
1000 dilution in PBST containing 1 % BSA into each well and incubated for another 1 h. 
Detection was carried out by adding 50 μl of p-nitrophenyl phosphate liquid substrate 
system (Sigma, MO) after washing. Color development was monitored with a plate 
reader (Dynex MRX II, Richfield, MN) every 10 min for 30 min at 405 nm. A standard 
curve was plotted using a sigmoidal fit (Figure S2.1) and concentrations of diluted samples 
were calculated. 
2.3.10 Evaluation of reconstituted bevacizumab from the complexes with trapping 
agents 
Complexes of bevacizumab and trapping agents at the optimal ratios were 
centrifuged and the supernatants were removed. Then, PBST was added into the 
centrifuged insoluble complexes. It was observed with the naked eye that all the 
complexes were dissolved immediately after vortexing for a few seconds. These solutions 
were analyzed by SE-HPLC and ELISA to determine the amount of soluble reconstituted 
proteins and their immunoreactivity. Solubility and immunoreactivity of bevacizumab 
after reconstitution were calculated by the following equations: 
ܵ݋݈ݑܾ݈݅݅ݐݕ	 ൌ ܥ݋݊ܿ݁݊ݐݎܽݐ݅݋݊	݋݂	ݏ݋݈ݑܾ݈݁	ܾ݁ݒܽ݅ܿݑݖܾ݉ܽ	ܫ݊݅ݐ݈݅ܽ	ܿ݋݊ܿ݁݊ݐݎܽݐ݅݋݊ ൈ 100	% 
 
ܫ݉݉ݑ݊݋ݎ݁ܽܿݐ݅ݒ݅ݐݕ	 ൌ ܥ݋݊ܿ݁݊ݐݎܽݐ݅݋݊	݋݂	݅݉݉ݑ݊݋ݎ݁ܽܿݐ݅ݒ݁	ܾ݁ݒܽܿ݅ݖݑܾ݉ܽ	ܥ݋݊ܿ݁݊ݐݎܽݐ݅݋݊	݋݂	ݏ݋݈ݑܾ݈݁	ܾ݁ݒܽ݅ܿݑݖܾ݉ܽ ൈ 100	% 
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where concentration of soluble bevacizumab and concentration of immunoreactive 
bevacizumab were determined by SE-HPLC and ELISA, respectively after reconstitution 
in PBST.  
2.3.11 Scanning electron microscopy (SEM) 
The surface morphology of PLGA microspheres was examined by Hitachi 
S3200N scanning electron microscope (Hitachi, Japan). The microspheres were first 
fixed on a brass stub using double sided adhesive carbon tape and then were made 
electrically conductive by coating with a thin layer of gold (~ 5 nm) for 120 s at 40 W. 
The images of microspheres were taken at an excitation voltage of 8 - 20 kV. 
 
 Results and Discussion 
In order to develop PLGA microspheres of bevacizumab and its Fab fragment for 
sustained release by active self-encapsulation, several factors governing loading and 
release kinetics must be considered. As a trapping agent, calcium (CA)-alginate, high 
molecular weight dextran sulfate (HDS) and other negatively charged polymers were 
investigated to use electrostatic interaction as a binding force since the antibodies are 
positively charged at neutral pH.  
2.4.1 Bevacizumab Fab fragments 
Although Lucentis® is an officially approved drug for wet AMD, its whole 
antibody version, Avastin® is commonly being used off-label in clinics for wet AMD due 
to its low cost. For research purpose, likewise, bevacizumab was used in this study owing 
to its cost-effectiveness. However, it is known that the whole antibody has a propensity to 
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aggregate induced by agitation [18,19] which is a step of active self-encapsulation to 
facilitate loading. Thus, Fab fragments enzymatically produced from the whole antibody, 
bevacizumab, were used in order to avoid agitation-induced aggregation and to mimic 
ranibizumab. 
In order to produce Fab fragments from the whole anti-VEGF antibody, 
bevacizumab, a commercial Fab fragment preparation kit was used (Figure 2.2A). To 
confirm the production of Fab fragments, SDS-PAGE was performed (Figure 2.2B). 
Bevacizumab was incubated for 2 and 6 h with an immobilized papain, which specifically 
cuts at the hinge region of an antibody, to observe the time dependency on digestion. In a 
non-reducing condition, a band for Fab fragments which have a molecular weight slightly 
smaller than 50 kDa was observed in the fraction of “flowthrough” from protein A 
column which captures only proteins with Fc portion. After eluting Fab fragments from 
the protein A column, the bound proteins were eluted using a low pH eluting buffer and 
run in a gel. In this fraction (Protein A elution), Fab fragments which are not eluted 
previously, Fc fragments which are slightly bigger than 50 kDa, partially digested 
antibodies (~100 kDa), and undigested whole antibodies (~150 kDa) were observed. 
Although not all of the antibodies were digested, digestion times greater than 6h were not 
tested as per the kit instructions. In a reducing condition, all the disulfide bonds between 
chains are broken, therefore, a half-size band of Fab fragments (~25 kDa) was observed 
in the fraction of “Protein A flowthrough.” In the fraction of “Protein A elution”, half-
size bands of Fab and Fc fragments (~25 kDa) and undigested heavy chains (~50 kDa) 
were observed as expected. For the future studies, the digestion time was fixed at 6h in 
order to ensure enough digestion, and to minimize damages by the enzyme. 
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2.4.2 Ca-alginate gel as a trapping agent 
Isoelectric points (pI) of bevacizumab and ranibizumab (Lucentis®) are 8.3 – 8.4 
[20,21] and 8.8 [22], respectively, which means they have a net positive charge at neutral 
pH or below. Ranibizumab is only different by six amino acids from the corresponding 
part of bevacizumab and one anionic residue is added in total [23], so the Fab fragment 
produced from bevacizumab should also be positively charged at neutral pH or below as 
well. Therefore, negatively charged polymers can serve as trapping agents for active 
loading of bevacizumab by electrostatic interaction. Alginic acid is an anionic 
polysaccharide found in the cell walls of brown algae, which can form insoluble gel when 
divalent cations such as Mg2+, Ca2+, Zn2+, Sr2+ and Br2+ are added by cross-linking the 
polymers [24]. Along with its negative charge, alginic acid is biodegradable, 
biocompatible and easily available [24,25], therefore it could be a good candidate of a 
trapping agent for bevacizumab. In the preliminary study, water-soluble sodium alginate 
(Na-alginate) was dissolved in an inner water phase of PLGA microspheres, then the 
resulting microspheres were pre-incubated with the divalent cation salts, CaCl2 or ZnCl2, 
for 24 h at 4°C, washed with water, and then actively loaded with Fab fragments in 10 
mM histidine buffer, pH 5.5, which is the buffer of Lucentis® and pore-closed. Loadings 
(w/w) were encapsulation efficiencies were too low (below 0.1 % and ~1 %, 
respectively). When Fab fragments were mixed with the same mass of Ca-alginate 
powders, over 80 % of Fab fragments were bound. The initial mass of Na-alginate added 
in the inner water phase was 10 % (w/w) of PLGA, and the mass of Fab fragments in 
loading solution was 5 % (w/w) of total microspheres, so the binding ratio of Fab 
fragments and alginate polymers should be enough assuming all the alginate was 
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encapsulated. However, the results of very low encapsulation efficiency (~1 %) revealed 
that most of alginate may have been removed during the solvent evaporation step and/or 
incubation step in the divalent cation salt solution. Loading and encapsulation efficiency 
slightly increased, to 0.4 % and 8.4 % respectively, without incubation in the divalent 
cation salt solution, therefore, it can be supposed that the considerable amount of Na-
alginate escaped from the microspheres rather than formed insoluble gel in the 
microspheres during the pre-incubation step. In order to prevent alginate from leaching 
out of microspheres, lyophilized Ca-alginate powders were prepared and suspended in an 
inner water phase of PLGA microspheres. Four different formulations were prepared: (A) 
10 % (weight/weight of polymer) Ca-alginate suspended in 50 % (weigh/volume of inner 
water phase) trehalose solution, (B) 10 % Ca-alginate suspended in 10 % trehalose 
solution, (D) 10 % Ca-alginate suspended in water, (D) 20 % Ca-alginate suspended in 
10 % trehalose solution. Trehalose acts as a porosigen, thus affecting pore structures of 
microspheres and presumably loading of Fab fragments. By suspending Ca-alginate 
powders in the inner water phase, high loading (2.8, 3.3, 4.1 and 4.0 %, respectively) and 
encapsulation efficiency (56.6, 65.7, 82.4 and 79.3 %, respectively in A-D) were obtained 
after active self-encapsulation steps (Figure 2.3). In the following in vitro release study, 
however, the initial burst release on day1 was ~60 % of the total loaded Fab fragments 
and the release stopped afterward. Sodium ions which are present in the human body and 
PBST (release medium) can dissolve insoluble Ca-alginate gel into liquid, therefore, they 
may be responsible for the high initial burst release. 
2.4.3 HDS as a trapping agent 
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As the second candidate of trapping agents, high molecular weight (~500 kDa) 
dextran sulfate (HDS) was investigated. Previously in our lab, HDS was employed as a 
trapping agent for successful active self-encapsulating PLGA microspheres of lysozyme 
and VEGF [13]. Sulfate groups of HDS have highly negative charges, so HDS can bind 
to Fab fragments of the opposite charge by electrostatic interaction.  
2.4.3.1 Fab fragment-HDS binding 
To determine the binding ratio of Fab fragments and HDS, they were complexed 
at varying ratios and the remaining free proteins in the supernatants were measured after 
centrifugation. The bound proteins to HDS formed insoluble pellets at the bottom of 
tubes and were able to be reconstituted to soluble proteins immediately when PBST is 
added. Among the tested ratios, most of Fab fragments (99.1%) were bound to HDS at 
the ratio of 1:0.1 (Fab fragment : HDS, w/w) (Figure 2.4). Interestingly, less proteins 
were bound to HDS at the higher ratios (1:0.2 – 1:1). This may be due to repelling force 
between highly negatively charged HDS polymers. This optimal ratio (1:0.1) of binding 
is ideal since only 10 % mass of HDS is needed to capture Fab fragments, therefore, not 
so much HDS needs to be encapsulated in PLGA microspheres.  
2.4.3.2 Active self-encapsulating PLGA microspheres with HDS and ZnCO3 
The formulations developed initially for lysozyme and VEGF in our lab contained 
3 % trehalose (w/w of polymer) as a porosigen and 4 % HDS as a trapping agent in an 
initial inner water phase and 3 % MgCO3 as an antacid. Therefore, half milliliter of 2 
mg/mL Fab fragments were loaded into 20 mg of this formulation for 48 h at 24°C. 
Loading and encapsulation efficiency were measured by quantifying the remaining 
proteins in the supernatants with SE-HPLC, which were 1.8 % and 36.9 %, respectively 
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(Figure 2.5 A and B). After the active self-encapsulation, in vitro release study was 
performed at the particle concentration of 3 mg/mL in PBST containing 1 % BSA for 
ELISA analysis. Considering the loading and the particle concentration in release study 
were low, measurement of release by SE-HPLC was not performed due to its low limit of 
detection. Release of immunoreactive Fab fragments from this formulation almost 
stopped at 34 % on day 7 (Figure 2.5 C). MgCO3 was known to maintain the 
microenvironmental pH in PLGA at around 7 [26]. On the other hand, it can be 
extrapolated that Fab fragment mimicking ranibizumab is stable at pH 5.5 which is the 
pH of the commercial Lucentis® formulation. Therefore, ZnCO3 (6 %) which maintains 
the microenvironmental pH in PLGA at 5 - 6 [26] was encapsulated in the HDS-PLGA 
microspheres instead of MgCO3. After the active self-encapsulation, it was observed by 
SEM that pores of the microspheres were closed and surface became smooth (Figure 
S2.2). Loading and encapsulation efficiency were slightly reduced to 1.2 % and 23.4 %, 
respectively (Figure 2.5 A and B), however, release of immunoreactive Fab fragments 
was continuous throughout the whole release study and by day56, the total cumulative 
release was 99.1 % of the loaded protein (Figure 2.5 C). This result showed the control of 
microenvironmental pH in PLGA can be a strategy to stabilize the encapsulated proteins 
and to result in continuous and complete release. However, loading and encapsulation 
efficiency were low, so these parameters still need to be improved. In addition, initial 
burst release on day1 from the HDS-PLGA microspheres with ZnCO3 was 41.7 %, and 
then release rate slowed down. The release rate needs to be near zero-order to maintain 
the concentration of antibodies at a constant level in the target site. 
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2.4.3.3 Effect of ZnCO3 content on loading 
In order to increase loading and encapsulation efficiency, the effect of ZnCO3 
content in microspheres on loading was investigated. The HDS-PLGA microspheres 
studied above which contain 6 % ZnCO3 resulted in almost complete release, therefore, 
6 % ZnCO3 is thought to be enough to stabilize the encapsulated proteins. However, it 
may be possible that high content of the basic salt increase pH in the pores during the 
active loading, thus resulting in low loading of Fab fragments as efficient loading occurs 
at pH in between the pKa of trapping agents and pI of proteins. Therefore, the content of 
ZnCO3 was reduced to 0, 3 or 4.5 %. As expected, HDS-PLGA microspheres without 
ZnCO3 showed the highest loading (2.7 %) among those probably because loading pH in 
the microspheres did not increase. Interestingly, however, loadings in the microspheres 
with 3 % and 4.5 % ZnCO3 were 0.9 % and 1.2 %, which were slightly lower than one 
(1.3 %) with 6 % ZnCO3 at the same condition. Overall, changing the content of ZnCO3 
did not much enhance both the loading and encapsulation efficiency (Figure 2.6 A). 
2.4.3.4 Effect of loading buffer pH on loading 
Similar to changing the basic salt content, the pH of the loading buffer was 
changed to test the effect on loading parameters. In addition to the initial pH 5.5 of 10 
mM histidine buffer, loading buffers of pH 4.5, 5.0 (10 mM acetate buffer) and 6.0 (10 
mM histidine buffer) were tested with all the other condition as previously used. 
However, the resulting loadings (1.5 %, 1.6 %, 1.3 % and 1.5 % for pH 4.5, 5.0, 5.5 and 
6.0, respectively) in those conditions did not appear to exhibit a pH-dependent pattern 
(Figure 2.6 B). These pH values were the initial pH of loading buffers, and it was 
observed later that the final pH of loading solutions after adding the proteins were all 
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similar (pH ~5.5) since the protein by itself has buffering capacity. However, adjusting 
final pH to the desired values was not performed since the addition of extreme pH 
adjusting solutions would destabilize the proteins. 
2.4.3.5 Effect of HDS content on loading 
As shown in Figure 2.4, Fab-HDS binding (99.1%) was the highest at 1:0.1 in the 
loading buffer (10 mM histidine buffer, pH 5.5) and it gradually reduced at the lower and 
higher ratios. Thus, there should be a certain ratio at which most HDS is available for 
binding of Fab fragments in microspheres. Since the encapsulation efficiency of HDS in 
microspheres is unknown, varying amount of HDS (0.3 % - 8 %, w/w of PLGA) was 
encapsulated and loadings of Fab fragments into these formulations were measured 
(Figure 2.6 C). A formulation with 1 % HDS resulted in the highest loading (2.1 %) and 
ones with the lowest (0.3 %) and highest (8 %) HDS content showed the lower loadings, 
which are 0.6 % and 1 %, respectively. It is supposed that the 1 % HDS content gives the 
optimal binding ratio with the proteins in loading solution as shown in the binding profile 
of Figure 2.4. Overall, loading and encapsulation efficiency were not significantly 
enhanced as desired. 
2.4.3.6 Effect of Fab concentration on loading 
Lastly, the effect of Fab fragment concentration in the loading buffer on 
loading/efficiency was studied. Formulations with 1 % and 2 % HDS were chosen 
because they demonstrated relatively higher loading of Fab fragments. Other conditions 
were fixed to the initial ones (10 mM histidine buffer, pH 5.5, and 6 % ZnCO3). Fab 
fragments of three different concentrations (4, 8, 16 mg/mL) in the fixed volume of 
loading buffer (0.125 mL) were loaded into 5 mg of 1 % and 2 % HDS-PLGA 
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microspheres through the same active self-encapsulation process as above. Higher 
concentration of proteins in loading solutions resulted in higher loading and formulations 
with 1 % HDS showed slightly higher loading than ones with 2 % HDS at the same 
loading concentration as expected (Figure 2.7). Loading in microspheres with 1 % HDS 
at 16 mg/mL Fab fragment was the highest (6.4 %) which seems promising, however, 
encapsulation efficiency was only 15.7 % which is the lowest among the same 
formulations. On the contrary, the formulation loaded with the lowest concentration (4 
mg/mL) of proteins showed the lowest loading (2.9 %) and the highest encapsulation 
efficiency (29.3 %). This opposite trend of loading and encapsulation efficiency was also 
observed in 2 % HDS microspheres. Considering all the resulting loadings and 
encapsulation efficiencies, changing the parameters above did not improve both loading 
and encapsulation efficiency simultaneously to the desired levels.  
2.4.4 Evaluating whole antibodies of bevacizumab 
Papain-digested Fab fragment from bevacizumab had been used because it 
mimics ranibizumab (Lucentis®) which is an officially approved drug for wet AMD at a 
much lower cost and whole antibody is known to be prone to aggregation induced by 
agitation [18,19] which is a step of active self-encapsulation. However, it is difficult to 
control quality of enzymatically produced Fab fragments in laboratory settings and 
considerable amount of the papain-digested Fab fragments dimerizes depending on 
concentration. From the soluble Fab fragment standards, the monomer content was 
measured by SE-HPLC, which only ranged from 56.0 to 66.5 % (Figure S2.3), and it is 
unknown how this considerable dimerization affects stability and activity of the proteins. 
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In order to avoid these uncertainties, we decided to use the whole antibody of 
bevacizumab instead of Fab fragments for all the following studies.  
2.4.5 Screening trapping agents for whole antibody 
From the above studies, it was revealed that HDS is promising as a trapping agent 
for active self-encapsulation of the therapeutic antibodies, but has some drawbacks which 
are low loading or low encapsulation efficiency, and undesirable release kinetics. 
Therefore, other trapping agents were tested as well. Several properties such as 
biocompatibility, biodegradability, and anionic charge property at loading pH were 
desired as selection criteria for trapping agents. Consequently, the following anionic 
polymers were chosen to test abilities as trapping agents: poly(acrylic acid) (PAA), 
poly(methacrylic acid) (PMAA), poly(styrenesulfonic acid) (PSSA), pectin, and 
carrageenan. These are commonly researched materials for drug delivery and meet the 
desirable criteria [27–31]. Firstly, their binding ability to bevacizumab was tested with 
the same condition as in Fab-HDS binding assay done previously (Section 2.3.5). Like 
HDS, bevacizumab bound optimally to the polymers at a specific ratio, except for PSSA 
to which most proteins bound at and beyond a certain ratio (Figure 2.8). The optimal 
ratios at which most proteins bound to the trapping agents ranged from 1:0.1 to 1:0.5 
(bevacizumab:trapping agent, w/w) which are acceptable because the trapping agents do 
not need to be encapsulated more than proteins in microspheres. Next, it was tested how 
much active bevacizumab can be recovered from the complexes after reconstitution in 
PBST. Among those complexes, the reconstituted bevacizumab from PAA, PMAA and 
pectin was completely soluble (101.7 %, 103.8 % and 104.0 %, respectively) and protein 
bound to PAA demonstrated the highest immunoreactivity (90.7 %) (Figure 2.9). 
 47 
 
Therefore, PAA was chosen to be encapsulated as another trapping agent in PLGA 
microspheres because it demonstrated high protein binding and desired properties of 
released proteins in terms of solubility and immunoreactivity. PAA was encapsulated at 
4 % and 8 % in PLGA microspheres with 6 % ZnCO3 and bevacizumab was loaded with 
the same active self-encapsulation process as before. Unfortunately, however, loadings 
and encapsulation efficiencies were extremely low, which were 0.27 % and 2.7 % for 4 % 
PAA formulation; and 0.16 % and 1.6 % for 8 % PAA formulation (Figure 2.10). Release 
study was not performed because the concentration of released proteins would be too low 
to be measured. 
 
 Conclusions 
In this chapter, we demonstrated that anionic polymers can serve as trapping 
agents for the anti-VEGF antibodies to develop active self-encapsulating PLGA 
microspheres. Ca-alginate enabled high loading and encapsulation efficiency of the 
proteins, but the release stopped after high initial burst release on day 1, which is 
undesirable. HDS-PLGA microspheres containing ZnCO3 as an antacid showed 
continuous and complete release of the immunoreactive anti-VEGF Fab fragments by 
day56. Despite changing several formulation parameters, their low loading and 
encapsulation efficiency were not significantly improved and the release kinetics needs to 
be more near zero-order to maintain the concentration of antibodies at a constant level in 
the target site. In an attempt to solve these issues, other anionic polymers were screened 
as trapping agents and active self-encapsulating PAA-PLGA microspheres were 
prepared, however, they resulted in very low loading and encapsulation efficiency. 
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In conclusion, our data suggested that active self-encapsulating PLGA 
microspheres were not suitable as controlled release systems of bevacizumab for wet 
AMD since they did not simultaneously meet all the criteria: high loading, high 
encapsulation efficiency, and near zero-order release of the immunoreactive antibodies 
even though they have been successfully utilized for controlled release of other protein 
drugs. Thus, we decided to investigate other strategies e.g. PLGA millicylindrical 
implants as controlled release formulations for bevacizumab as discussed in the next 
chapters. 
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Figure 2.1: Loading schematic comparison of passive loading and active self-
encapsulation in PLGA microspheres. 
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Figure 2.2: Preparation of Fab fragments from bevacizumab. Schematic for digesting 
Fab fragments using immobilized papain. Modified from the manual of Pierce™ Fab 
Preparation Kit (A). SDS-PAGE of non-reduced and reduced proteins from papain 
digestion of bevacizumab (B).  
 51 
 
 
Figure 2.3: Loading (w/w) and encapsulation efficiency of Fab fragments into Ca-
alginate PLGA microspheres. Each formulation has an inner water phase (400 µL) of 
(A)20 mg of Ca-alginate powders dispersed in 50 % trehalose solution, (B)20 mg of Ca-
alginate powders dispersed in 10 % trehalose solution, (C)20 mg of Ca-alginate powders 
dispersed in dH2O, and (D)40 mg of Ca-alginate powders dispersed in 10 % trehalose 
solution. The values are expressed as mean ± SD, n=2. 
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Figure 2.4: Fab-HDS binding profile. Fab fragments were mixed with HDS at different 
mass ratios and incubated for 1 h at room temperature. Soluble free Fab fragments were 
quantified by SE-HPLC after centrifugation. The values are expressed as mean ± SD, 
n=2. 
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Figure 2.5: Effect of base on HDS-PLGA formulations. Loading (w/w, A), 
encapsulation efficiency (B) of Fab fragment, and immunoreactive Fab fragment release 
kinetics of HDS-PLGA microspheres containing 3 % MgCO3 (yellow, ●) and 6 % 
ZnCO3 (blue, ○) as an antacid. The values are expressed as mean ± SD, n=3. 
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Figure 2.6: Effect of formulation parameters for HDS-PLGA. ZnCO3 content (A), pH 
of loading buffer (B), and HDS content (C) on loading of Fab fragments. The values are 
expressed as mean ± SD, n=2. 
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Figure 2.7: Effect of Fab fragment concentration in loading solution on loading (w/w) 
and encapsulation  efficiency. Fab fragments were loaded at different concentration into 
HDS-PLGA microspheres containing 1 % HDS (black) and 2 % HDS (white). The values 
are expressed as mean ± SD, n=2. 
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Figure 2.8: Bevacizumab-trapping agent binding profiles. Bevacizumab were mixed 
with PAA (A), PMAA (B), PSAA (C), pectin (D), and carrageenan (E) at different mass 
ratios and incubated for 1 h at room temperature. Soluble free bevacizumab was 
quantified by SE-HPLC after centrifugation. The values are expressed as mean ± SD, 
n=2. 
  
 57 
 
 
Figure 2.9: Reconstituted bevacizumab from complexes of trapping agents. 
Bevacizumabs bound to trapping agents which are PAA (1:0.1), PMAA (1:0.1), PSSA 
(1:0.1), pectin (1:0.5) and carrageenan (1:0.2) were reconstituted in PBST and their 
solubility (black bars) and immunoreactivity (white bars) were analyzed by SE-HPLC 
and ELISA. The values are expressed as mean ± SD, n=2. 
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Figure 2.10: Loading (w/w) and encapsulation efficiency of bevacizumab in 4 % and 
8 % PAA-PLGA microspheres. The values are expressed as mean ± SD, n=2. 
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Figure S2.1: ELISA standard curves of Fab fragments (A) and whole antibodies of 
bevacizumab (B). 
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Figure S2.2: SEM images of HDS-PLGA microspheres containing 6 % ZnCO3 before 
(A) and after (B) self-encapsulation process of Fab fragments. 
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Figure S2.3: Monomer content as a function of concentration of Fab fragments. 
Monomer content (%) of Fab fragments prepared by papain digestion is dependent on 
concentration. 
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Chapter 3: PLGA millicylindrical implants of bevacizumab 
 Abstract 
To reduce the administration frequency of bevacizumab for wet age-related 
macular degeneration (wet AMD), poly(lactic-co-glycolic acid) (PLGA) millicylindrical 
implants were evaluated as sustained release formulations of the protein. To prepare 
PLGA implants, an anhydrous solvent-extrusion method in which drug powders are 
suspended in PLGA/acetone solution was employed. The powders directly lyophilized 
and ground from commercial Avastin® solution without any change in the composition 
resulted in high recovery when re-dissolved in the aqueous buffer (99 %) and extracted 
from implants (97 %). The implants loaded with 15 % bevacizumab from this powder 
released 94 % of the encapsulated proteins in 1 day, which is undesirable. In order to 
reduce this initial burst and to slow down the release, trehalose was removed through 
buffer exchange since its abundance increases the volumetric loading of total drug 
powder above the percolation threshold. However, the recovery of protein from the 
trehalose free powder was only 67 % when the powder was reconstituted in the aqueous 
buffer, and only 58 % was recovered by extracting the protein from the implants. The 
release rate was slower, but the total cumulative release was only 53 % out of the soluble 
extracted loading, suggesting that trehalose has anti-aggregation effects during the 
powder and implant preparation and during release. With the powder containing 
trehalose, dependency of release rate on loading was tested and the implant loaded with 
3 % bevacizumab showed the most promising release kinetics among the implants. To 
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increase the loading of bevacizumab while maintaining a continuous release profile and 
preventing aggregation, the effort to optimize trehalose content in the powder was made.  
It was found that a 1.5:1 ratio (trehalose : bevacizumab, w/w) still prevents aggregation 
of bevacizumab and yielded adequate recovery of soluble protein from cryomilled 
powder. With the optimized trehalose content in the powder, the implants of various 
powder loading were tested and the release rate was slower than the initial implants with 
the corresponding loading of bevacizumab from Avastin® solution. The implant loaded 
with 6 % bevacizumab with the optimized trehalose content showed a biphasic release 
profile with the total cumulative release of 81 % which was the best release profile 
among the tested implants. Hence, despite improvement in stability of the mAb during 
encapsulation, further work is needed to achieve near zero-order release of stable mAb, 
thus maintaining the concentration of bevacizumab longer in the therapeutic window at 
the target site.  
 
 Introduction 
Over the past decade, anti-vascular endothelial growth factor (VEGF) therapy has 
been a common treatment strategy for wet AMD [1]. In wet AMD, overexpression of 
VEGF is responsible for abnormal growth of blood vessels under the macula, resulting in 
central vision loss [2]. Therefore, inhibition of VEGF activity by anti-VEGF agents is a 
key to treat wet AMD. Macugen® (pegaptanib, anti-VEGF aptamer) which is the first 
FDA-approved anti-VEGF agent for wet AMD in 2004 was able to slow down 
progression of the disease, but did not improve visual acuity significantly [3]. Later 
developed anti-VEGF protein formulations for wet AMD, which are Lucentis® 
 67 
 
(ranibizumab, anti-VEGF monoclonal antibody Fab fragment) and Eylea® (aflibercept, a 
recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 
extracellular domains fused to the Fc portion of human IgG1), demonstrated better results 
compared to Macugen®, and are currently the most used drugs for wet AMD [1,4]. 
Another anti-VEGF agent which is one of the most used drugs for the disease is Avastin® 
(bevacizumab, anti-VEGF whole monoclonal antibody). It is officially approved for 
intravenous infusion to treat certain types of cancer, however has also been widely used 
off-label for intravitreal injection to treat wet AMD due to its lower price relative to 
Lucentis® and Eylea® [1,5]. The intravitreal injection of these anti-VEGF agents is 
usually given once a month (every 4 weeks), but this is very inconvenient for patients [6] 
and may induce infection, inflammation, and hemorrhage [7]. Therefore, if one can 
extend the therapy duration, and thus reduce administration frequency, it will reduce the 
associated inconvenience and risks. 
In the previous chapter, the efforts to increase loading and encapsulation 
efficiency of bevacizumab with the active self-encapsulating PLGA microspheres were 
not successful. In order to overcome the issues, in this chapter, PLGA millicylindrical 
implants were employed as depot systems for sustained release of bevacizumab. Loading 
of drugs into PLGA implants is accomplished by simply suspending drug powders in the 
PLGA/acetone solution, so the encapsulation efficiency is theoretically 100 %, and any 
desired loading can be achieved [8,9]. Ozurdex®, a PLGA implant, is an FDA-approved 
intravitreal injectable device for controlled release of dexamethasone [10], providing a 
clinical precedent for use of PLGA implants in the eye. The device is intravitreally 
injected via a special pen-like applicator without any surgical incisions.  
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One of the main drawbacks of PLGA formulations for protein encapsulation is the 
formation of an acidic microenvironment during release due to the degraded acid 
byproducts in the polymer, which easily destabilizes the encapsulated proteins and results 
in incomplete release. This issue has been overcome by co-encapsulation of poorly 
soluble basic salts to neutralize the acids and to achieve a more continuous and higher 
total protein release [8,11,12]. Similarly, the use of anhydrous microencapsulation when 
preparing millicylindrical devices similar to Ozurdex® was developed by our group in 
order to minimize the stress during encapsulation of the organic solvent contact with a 
mobilized protein as occurs during common methods of encapsulation [12–14]. In order 
to encapsulate water-soluble proteins in PLGA implants, the micronized protein powder 
is first suspended in PLGA solution. Drying (e.g. lyophilization) and milling processes, 
which also can damage proteins, are needed to prepare protein powder for encapsulation. 
To protect proteins from damage by these stresses, stabilizers need to be co-incorporated. 
Sugars such as trehalose and sucrose have been widely used in protein formulations as 
stabilizers. Although the stabilizing mechanism of sugars for proteins has not been fully 
understood, three theories have been proposed, which are the “vitrification”, “preferential 
exclusion” and “water replacement” theories [15–17].  
High loading of any water-soluble components in the polymer results in faster 
release [18,19]. Therefore, in this chapter, dependency of release rate on loading was 
tested, and we sought to optimize the ratio of sugar to protein so that both high stability 
and desirable release rate of bevacizumab would be possible at the same time. 
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 Materials and Methods 
3.3.1 Materials 
The Avastin®, commercial solution of bevacizumab was purchased from the 
University of Michigan Hospital pharmacy and used within its shelf-life period. PLGA 
50:50 (inherent viscosity = 0.64 dL/g and Mw = 54.3 kDa, ester terminated) was 
purchased from LACTEL Absorbable Polymers (Birmingham, AL). Trehalose dihydrate 
(trehalose), MgCO3, guanidine hydrochloride, DL-dithiothreitol (DTT), ethylenediamine-
tetraacetic acid (EDTA), Na2HPO4 and NaH2PO4, were purchased from Sigma-Aldrich 
Chemicals (St. Louis, MO). Tween 80 (10%), acetone, KH2PO4, K2HPO4, KCl, 
phosphate buffered saline (PBS), Amicon Ultra-15 Centrifugal Filter Units (10,000 
MWCO), silicone rubber tubing, and Coomassie plus reagent were purchased from Fisher 
Scientific (Hanover Park, IL).  
3.3.2 Preparation of bevacizumab powder 
The buffer of Avastin® solution containing bevacizumab and excipients was 
exchanged into 51 mM sodium phosphate buffer (pH 6.2) by using Amicon Centrifugal 
Filter Units (10,000 MWCO) to remove trehalose. Then, different levels of trehalose 
were added (weight of trehalose : weight of bevacizumab = 0, 0.1, 0.5, 1 and 1.5 : 1) and 
the solution was diluted with 51 mM sodium phosphate buffer (pH 6.2) for the final 
bevacizumab concentration of 5 or 25 mg/mL and lyophilized. The solid was then ground 
by CryoMill (Retsch, Germany) at 30 Hz for 30 min and sieved through 90-μm screen 
(Newark Wize Wearing, Newark, NJ). High trehalose content protein powder was 
prepared (ratio of 2.4 to 1, trehalose : bevacizumab) by lyophilizing the commercial 
Avastin® solution without buffer exchange, and then ground and sieved. 
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3.3.3 Preparation of PLGA millicylindrical implants with bevacizumab 
The resulting bevacizumab powder was suspended into 50 % (w/w) PLGA 
solution in acetone with 3% (w/w) MgCO3 in a 2 mL centrifuge tube, then mixed and 
transferred into a 3 mL syringe. The suspension was extruded into silicone rubber tubing 
(I.D. = 0.8 mm), then dried at room temperature for 48 h followed by vacuum drying at 
40°C and -23 in. Hg vacuum for an additional 48 h. The final dried implants were 
obtained by removal of silicone tubing and were cut into segments of a desired length for 
future use.  
3.3.4 Measurement of bevacizumab loading in implants 
Implants (3-5 mg) were dissolved in 1 mL of acetone for 1 h and centrifuged to 
precipitate out the proteins. PLGA, dissolved in supernatant, was removed and the 
protein pellet was washed with acetone and centrifuged three times more to remove any 
residual PLGA. The pellet was then air dried, reconstituted in 1 mL of PBST (phosphate 
buffered saline with 0.02 % Tween-80, pH 7.4) at 37°C overnight and analyzed by size-
exclusion high-performance liquid chromatography (SE-HPLC). The condition of SE-
HPLC to quantify monomer and soluble aggregates was followed as previously described 
[20] with slight modifications. The mobile phase (0.182 M KH2PO4, 0.018 M K2HPO4, 
and 0.25 M KCl, pH 6.2) was run at a flow rate of 0.5 mL/min through a column (TSK-
GEL G3000SWxl; Tosoh Bioscience, Japan), and elution was monitored at 280 nm. The 
volume of injection was 50 µL, and the running time was 30 minutes. All samples for 
SE-HPLC were filtered through 0.45 µm protein low binding filter. Extracted loading and 
loading efficiency were calculated by the following equations. 
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Extracted	loading	ሺ%ሻ ൌ Weight	of	extracted	bevacizumabWeight	of	total	implant 	ൈ 100	% 
 
Loading	efficiency	ሺ%ሻ ൌ Extracted	loadingTheoretical	loading	ൈ 100	% 
 
3.3.5 In vitro release study of bevacizumab from implants 
Implants (1 cm long, 6-8 mg) were added in 1.5 mL centrifuge tubes with 1 mL of 
PBST and incubated at 37°C without agitation, as agitation was found to cause insoluble 
aggregation of the antibody [21,22]. The release medium was replaced with fresh 
medium at select time points. The amount of released bevacizumab at each time point 
was measured by SE-HPLC and calculated as percentage of the released amount out of 
the extracted loading of soluble bevacizumab 
3.3.6 Evaluation of residual bevacizumab in implants 
At the end of release study, the remaining bevacizumab was extracted by the same 
procedure used to measure protein loading after lyophilizing the remaining polymer. The 
protein pellet was then reconstituted in PBST and incubated at 37°C overnight to 
determine the soluble fraction of the protein remained in the polymer. After 
centrifugation, the supernatant was collected and the remaining insoluble precipitates 
were dissolved in denaturing solvent (6 M guanidine hydrochloride/1 mM EDTA) at 
37°C for 1 h to determine non-covalent protein aggregates. After centrifuging and 
collecting supernatant, the remaining insoluble precipitates were dissolved again in 
denaturing/reducing solvent (6 M guanidine hydrochloride /1 mM EDTA/10 mM DL-
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dithiothreitol) to measure covalent protein aggregates formed by disulfide bonds. 
Concentration of protein aggregates in each step was measured by Coomassie plus 
protein assay. All measurements were performed in triplicate and bevacizumab standards 
were dissolved in the same solvent used for each analysis. 
3.3.7 Measurement of the effect of trehalose on aggregation of bevacizumab in 
powders 
Bevacizumab powder with the various ratios of trehalose to bevacizumab (0, 0.1, 
0.5, 1, 1.5 and 2.4:1) were dissolved in PBST at 37°C overnight. The soluble fraction of 
protein was measured by SE-HPLC to determine the effect of trehalose on aggregation of 
bevacizumab. 
3.3.8 Scanning electron microscopy (SEM) 
The surface morphology of PLGA microspheres was examined by Hitachi 
S3200N scanning electron microscope (Hitachi, Japan) (Figure S3.1). The microspheres 
were first fixed on a brass stub using double sided adhesive carbon tape and then were 
made electrically conductive by coating with a thin layer of gold (~ 5 nm) for 120 s at 40 
W. The images of microspheres were taken at an excitation voltage of 8 - 20 kV. 
 
 Results and Discussion 
3.4.1 Evaluation of bevacizumab loaded implants with trehalose 
PLGA implants were formulated for sustained local delivery of bevacizumab. 
First, commercial Avastin® solution was lyophilized as is, then ground and sieved to 
prepare the bevacizumab powder. The formulation of Avastin® originally contains 2.4 
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times as much trehalose as bevacizumab, polysorbate 20, and buffer salts as excipients, as 
shown in Table 3.1. Bevacizumab lyophilized from the original Avastin® solution 
without any changes in its composition was loaded into PLGA implants at 15 % which is 
equivalent to 55.4 % loading of total protein powder due to the excipients. For all 
formulations, a poorly soluble base, MgCO3 was also added into implants at 3 % (w/w) 
as an antacid to stabilize loaded proteins by preventing low pH degradation created by 
acid by-products from degradation of PLGA during release [8,12]. When the powder was 
simply dissolved in PBST, 99 % of soluble bevacizumab was recovered. Of the extracted 
powder from the implants, 97 % was soluble in PBST (Figure 3.1 A). Therefore, it is 
concluded that bevacizumab from the powder and extract is quite stable in terms of 
aggregation propensity. But most of the loaded proteins (94 %) were released on day 1 
(Figure 3.1 B). It is thought that there is a percolation threshold of the bevacizumab 
loading, far below 15 %. Above the percolation threshold, the majority of drug particles 
are connected to each other and create water channels rapidly due to their high water 
solubility, so when water uptake starts at the beginning of release study the drug 
molecules will diffuse out through the rapidly formed water channels, thus creating the 
high initial burst release [18,19]. 
3.4.2 Evaluation of bevacizumab loaded implants without trehalose 
Therefore, to reduce the release rate while maintaining the protein loading, the 
osmotically active trehalose, which occupies 64.9 % mass of the protein powder 
lyophilized from the original Avastin® solution (Table 3.1), was removed by buffer-
exchange into 10 mM histidine buffer which was a loading buffer for the active self-
encapsulating PLGA microspheres in Chapter 2. Without trehalose, 67 % of soluble 
 74 
 
bevacizumab was recovered when the powder was dissolved in PBST, and only 58 % 
extracted protein was soluble from the implant after encapsulation, which is equivalent to 
8.7 % extracted loading (Figure 3.2 A). This implant batch showed very slow release 
during the release study period and released only 31 % bevacizumab out of theoretical 
loading (15 %) by the end of release (Figure 3.2 B and Table 3.2), which is still only 
53 % of the extracted loading (8.7 %). To analyze the remaining protein in polymer, the 
antibody was extracted from the implants after the release study. Non-covalent aggregate 
and covalent aggregate by disulfide bonds were 40 % and 35 %, respectively, with a total 
recovery of 106 % (Table 3.2). Aggregation of bevacizumab during cryomilling, 
preparation of implants, and the release study is thought to be attributed to the absence of 
trehalose in the drug powders since the extracted loading efficiency and total cumulative 
release of the implants with the presence of trehalose were both significantly higher. 
3.4.3 Dependency of release kinetics of bevacizumab with trehalose on loading 
From the formulations with and without trehalose, it is concluded that the 
presence of trehalose prevents aggregation of bevacizumab during cryomilling, implant 
preparation, and the release study. However, the implant loaded with 15 % bevacizumab 
and all the Avastin® excipients demonstrated high initial burst release due to the loading 
well above the percolation threshold. therefore, the implants with 3, 6, and 10 % loadings 
(w/w) of bevacizumab which are equivalent to 11.1, 22.2, and 37.0 % loading of total 
protein powder, respectively, were tested to evaluate dependency of release kinetics on 
loading. Extracted loading efficiencies calculated from extracted loadings ranged from 92 
to 100 % (Table 3.3). Release rate of bevacizumab from these implants increased as 
protein loading increased (Figure 3.3). The initial burst release on day 1 from 10 and 
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15 % loaded implants were 66 and 94 %, and was significantly higher than ones from 3 
and 6 % loaded implants, which were 7.0 and 4.6 %. Therefore, there must be the 
percolation threshold between 6 and 10 % bevacizumab loadings (22.2 and 37.0 % of 
total powder loadings). Above the percolation threshold, pure diffusion-through-channel 
release is expected to be the dominant release mechanism described in the section 3.4.1. 
Below the percolation threshold, on the other hand, drug particles are not connected in 
the polymer matrix, and thus form isolated water pores when water dissolves the drug 
particles. The isolated water pores start to swell because of osmotic pressure created by 
the osmotically active water-soluble components of drug powders and induce more water 
uptake. Finally, the swollen pores are ruptured and form microcracks which connect the 
adjacent pores, and then the drug molecules can be released through the interconnected 
pores. These steps involved in the formation of channels with microcracks induced by 
osmotic pressure are relatively slower than those formed when above the percolation 
threshold, thus acting as rate limiting step for drug release [18,19]. Therefore, the initial 
burst release is relatively low and following release rate is also slow because it is 
dominantly driven by osmotic pressure. The implants loaded with 3 % bevacizumab 
showed the most promising release profile which was continuous for 6 weeks with low 
initial burst and 62 % of total cumulative release. The incomplete total release from 
implants with lower loading is attributed to less homogeneous diffusion of MgCO3 into 
the pores formed by drug particles which creates some acidic pores by polymer 
degradation during release period, thus finally destabilizing proteins [23]. Most of the 
residual proteins analyzed by extraction were non-covalent aggregates, which was 14 % 
and total recovery was 72 % (Table 3.4). 
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As a control, the implant loaded with 15 % of buffer-exchanged (trehalose-
removed) bevacizumab into 51 mM sodium phosphate (pH 6.2) which is the buffer of 
Avastin® solution, not into 10 mM histidine buffer as in the above section, was also 
tested for comparison. Only 60 % soluble protein was recovered from the implant after 
encapsulation, which is equivalent to 9.0 % extracted loading (Table 3.3). The implant 
demonstrated very slow release during the whole release study period and released only 
22 % bevacizumab out of the soluble extracted loading by the end of release, as seen in 
Figure 3.3 and Table 3.4. Therefore, it was reaffirmed that trehalose works as a stabilizer 
against aggregation of the proteins. To analyze the remaining protein in polymer, the 
antibody was extracted from the implants after the release study. Soluble residual protein 
in PBST, non-covalent aggregate and covalent aggregate by disulfide bonds were 1.3 %, 
40 % and 1.6 %, respectively, with a total recovery of only 56 % (Table 3.4). The 
remaining protein, which was not recovered, could have formed insoluble aggregates e.g. 
covalent non-disulfide bonds, or hydrolysis products not detected by the SE-HPLC in the 
release media.  
3.4.4 Effect of trehalose on aggregation of bevacizumab in powders 
The presence of trehalose in the drug powder stabilized bevacizumab in the 
implants, but it also increased release rate undesirably since the commercial Avastin® has 
considerable amount of trehalose compared to bevacizumab, whose weight ratio is 2.4:1 
(2.4:1 powder). Therefore, we sought to optimize the ratio so that both high stability and 
desirable release rate of bevacizumab would be possible at the same time. To determine 
the optimal ratio of trehalose to bevacizumab in the protein powder, buffer-exchanged 
bevacizumab was mixed with trehalose at various ratios before preparing the micronized 
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drug powder, as used for encapsulation.  Then, the soluble protein in the powder when 
dissolved in PBST was measured by SE-HPLC (Figure 3.4 and Figure S3.2). The powder 
prepared from commercial Avastin® resulted in 99 % recovery of soluble bevacizumab 
and 98.0 % was recovered from the powders with the reduced ratio of 1.5:1 w/w 
trehalose : protein (1.5:1 powder). Further reducing trehalose in the powder at a 
trehalose : protein level of 1:1 resulted in only 76 % bevacizumab solubilized and the 
absence of trehalose resulted in only 70 % soluble protein in the powder. Therefore, the 
1.5:1 powder was selected for the next step preparation of implants to maintain the 
stability of bevacizumab while slowing down the release. 
3.4.5 Evaluation of implants with optimized trehalose content 
To compare release rate of the implants prepared with 1.5:1 w/w trehalose : 
bevacizumab powder to the previous set of implants with 2.4:1 powder, implants having 
the same loading of bevacizumab (3,6,10 and 15 %) were tested. Loading efficiencies of 
extracted soluble bevacizumab ranged from 91 – 94 %, which were slightly lower than 
the implants with 2.4:1 powder (Table 3.5). The release rate of each implant with the 
same bevacizumab loading as in the implants with 2.4:1 powder was slower as expected 
due to lower total powder loadings (8.3, 16.7, 27.8 and 41.7 %, respectively) with 
reduced trehalose content (Figure 3.5). Release rate from 3 % bevacizumab loaded 
implant was very slow and total cumulative release was only 21 % when it stopped on 
day 42. The implants loaded with 10 and 15 % bevacizumab loading released their 
proteins very fast as expected because their total powder loading (27.8 and 41.7 %) 
clearly exceeded the percolation threshold in the polymer matrix. From evaluating the 
initial release from the previous set of the implants with the 2.4:1 powder, the percolation 
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threshold was likely in the range between 22.2 and 37.0 % of total powder loading. The 
implant loaded with 6 % of bevacizumab also showed low initial burst release (7.2 %) on 
day 1 since the total solids loading was lower than the assumed percolation threshold. 
Among this set of implants, one loaded with 6 % bevacizumab showed the most 
promising overall release profile, although the release rate was not constant as desired 
during the whole release period for an ideal formulation. The trehalose content cannot be 
reduced any further due to instability of bevacizumab in the powder, and therefore, other 
strategies are needed to achieve high loading and near zero-order release profile at the 
same time. 
 
 Conclusions 
In this study, bevacizumab was loaded into PLGA millicylindrical implants to 
reduce its administration frequency. We demonstrated that trehalose in the bevacizumab 
powder directly lyophilized from the commercial Avastin® formulation prevents the 
proteins from aggregation in the powders and PLGA implants. With the absence of 
trehalose, a significant portion of bevacizumab was aggregated during the preparation of 
powders and implants, and the release study. With trehalose added, despite its stabilizing 
effect, the implants loaded with 10 % or higher bevacizumab resulted in undesirably fast 
release since the water-soluble trehalose occupies the most weight of drug powder, and 
the total drug powder loading was above the percolation threshold. The implants loaded 
with 3 % bevacizumab showed the most promising release kinetics, but the loading and 
incomplete total cumulative release still need to be improved. To increase loading while 
maintaining a good release kinetics and stability of the proteins, the lower contents of 
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trehalose in the drug powder were tested and it was found that the ratio of 1.5:1 
(trehalose : bevacizumab) provides the comparable anti-aggregation effect. From this 
optimized content of trehalose, the implants with various loadings (3, 6, 10, and 15 %) of 
bevacizumab were evaluated and exhibited the same dependency of release rate on 
loading with slightly slower release.  
In conclusion, trehalose was found to have anti-aggregation effect for 
bevacizumab and the release kinetics can be controlled by changing the loading of total 
drug powders. In order to increase loading and simultaneously to improve the release 
kinetics, further optimizations will be needed, and those efforts will be discussed in the 
next chapter.  
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Table 3.1: Composition in 4 mL of Avastin® solution. 
Composition Weight (mg) Dry weight percentage (%) 
Bevacizumab 100 27.1 
Trehalose dihydrate 240 64.9 
Polysorbate 20 1.6 0.4 
Sodium phosphate, monobasic, 
monohydrate 23.2 6.3 
Sodium phosphate, dibasic, anhydrous 4.8 1.3 
 
 
Table 3.2: Summary of cumulative release and aggregation behavior of proteins from 
the implants loaded with 15% bevacizumab of the powders with buffer exchange. Data 
reported as mean ± SD, n=2. 
Cumulative release (%) Non-covalent aggregate (%) 
Covalent 
aggregate (%) Total recovery (%)
31 ± 4 40 ± 6 35 ± 1 106 ± 4 
 
 
Table 3.3: Loading of implants prepared from bevacizumab powder with and without 
trehalose. Data reported as mean ± SD, n=3. 
Trehalose:bevacizumab 
 in powder (w/w) 
Theoretical 
loading (%) 
Extracted loading 
(%) 
Loading efficiency 
(%) 
2.4:1 
3 2.8 ± 0.2 92 ± 5 
6 6.0 ± 0.8 100 ± 13 
10 9.9 ± 0.6 99 ± 7 
15 14.5 ± 1.5 97 ± 11 
0:1 15 9.0 ± 0.3 60 ± 3 
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Table 3.4: Summary of cumulative release and aggregation behavior of bevacizumab 
from implants prepared from protein powder with and without trehalose. Data reported 
as mean ± SD, n=3. 
Trehalose 
:bevacizumab 
in powder 
(w/w) 
Theoretical 
loading 
(%) 
Cumulative 
release (%) 
Soluble 
residue 
(%) 
Non-
covalent 
aggregate 
(%) 
Covalent 
aggregate 
(%) 
Total 
recovery 
(%) 
2.4:1 3 57 ± 15 0 14 ± 5 0.9 ± 0.9 72 ± 18 
0:1 15 13 ± 1 1.3± 2.3 40 ± 20 1.6 ± 1.7 56 ± 23 
 
 
Table 3.5: Loading of implants prepared from bevacizumab powder with the ratio of 
1.5:1 w/w trehalose:bevacizumab. Data reported as mean ± SD, n=3. 
Trehalose:bevacizumab 
 in powder (w/w) 
Theoretical 
loading (%) 
Extracted loading 
(%) 
Loading efficiency 
(%) 
1.5:1 
3 2.7 ± 0.0 91 ± 1 
6 5.6 ± 0.2 93 ± 4 
10 9.2 ± 0.2 92 ± 3 
15 14.1 ± 0.7 94 ± 5 
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Figure 3.1: Recovery of soluble bevacizumab (A) from powder (blue bar) and extract 
from implant (yellow bar), and in vitro release study (B) of the implants loaded with 
15% bevacizumab of the lyophilized Avastin® powders (trehalose : bevacizumab = 
2.4:1, w/w). Data reported as mean ± SD, n=2. 
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Figure 3.2: Recovery of soluble bevacizumab (A) from powder (blue bar) and extract 
from implant (yellow bar), and in vitro release study (B) of the implants loaded with 
15% bevacizumab of the powders with buffer exchange (no trehalose). Data reported 
as mean ± SD, n=2. 
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Figure 3.3: Release kinetics of bevacizumab from implants prepared with original 
Avastin® powder (solid line) and buffer-exchanged bevacizumab powder without 
trehalose (dashed line). Theoretical loadings of each formulation were 3% (●), 6% (○), 
10% (▼), 15% (∆) and 15% (■). Symbols represent mean ± SD, n=3. 
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Figure 3.4: Soluble bevacizumab from cryomilled powder prepared with the different 
ratio of trehalose to bevacizumab (w/w). Each bar represents mean ± SD, n=3. 
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Figure 3.5: Release kinetics of bevacizumab from implants prepared with buffer-
exchanged bevacizumab powder with the ratio of 1.5 to 1 w/w trehalose:bevacizumab 
and PLGA 75:25. Theoretical loading of each formulation was 3% (●), 6% (○), 10% 
(▼), and 15%(∆). Symbols represent mean ± SD, n=3. 
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Figure S3.1: SEM images of PLGA millicylindrical implants (A: cross-section,  B: 
lateral surface). 
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Figure S3.2: Soluble bevacizumab from powder prepared with the different ratios of 
trehalose to bevacizumab (w/w) prepared on a small scale. Each bar represents mean ± 
SD, n=3. 
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Chapter 4: Coated PLGA implants for controlled release of 
bevacizumab 
 Abstract 
Wet age-related macular degeneration (AMD) is a condition in which new 
abnormal blood vessels grow under the macula, thus displacing the macula from its 
normal position, and resulting in rapid central vision loss. The growth of abnormal blood 
vessels under the retina is stimulated by overexpression of vascular endothelial growth 
factor (VEGF), therefore, anti-VEGF therapies have been developed to treat wet AMD. 
Intravitreal injections of the anti-VEGF agents are typically given every 4 weeks, but this 
is very inconvenient and repeated injections may induce infection, inflammation and 
hemorrhage. Sustained release formulations of the anti-VEGF agents can reduce 
administration frequency for patient convenience and minimize the risks while 
maintaining the therapeutic concentration in the vitreous. 
Poly (lactic-co-glycolic acid) (PLGA) is the most common and extensively 
researched polymer which has been used in several FDA-approved medical devices for 
long-term controlled release due to its biodegradability, biocompatibility and ability to 
provide desirable release kinetics. Injectable PLGA implants such as millicylinders has 
been used to deliver a number of stabilized protein drugs. Therefore, in this research, 
PLGA millicylindrical implants were employed to develop sustained release formulations 
of bevacizumab (Avastin®), a marketed anti-VEGF agent. To achieve near zero-order 
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release kinetics, with high loading of the protein and osmotically active excipients, the 
implants were coated with pure PLGA. Release kinetics of bevacizumab from implants 
with different PLGA concentrations in the coating solution were studied and it was 
observed that higher PLGA concentrations in a coating solution resulted in slower release 
of the antibodies. The implants coated with 30 % and 50 % PLGA demonstrated 
continuous in vitro release kinetics under physiological conditions over six weeks with 
total cumulative release of 82 ± 8 and 89 ± 4 % (mean ± SD, n=3), respectively. Analysis 
of the released antibodies by size-exclusion chromatography (SEC), enzyme-linked 
immunosorbent assay (ELISA) and circular dichroism (CD) showed little change in 
monomer content, immunoreactivity, and secondary structure during the 6-week release 
period. 
 
 Introduction 
Wet AMD is a condition in which new abnormal blood vessels grow and leak 
fluid, or blood, behind the macula. This leads to macula displacement, and rapid central 
vision loss. AMD is a major cause of vision loss in developed countries, especially in 
people 60 or older. There are two forms of AMD: the wet and dry form. The wet form of 
AMD accounts for only 10 % of the cases, but is responsible for 90 % of vision loss, 
whereas the more common dry form results in relatively mild symptoms [1–4]. In wet 
AMD, the growth of abnormal blood vessels under the retina is stimulated by 
overexpression of VEGF. Therefore, anti-VEGF therapies have been developed to 
neutralize VEGF activity. The first FDA-approved anti-VEGF agent was Macugen® 
(pegaptanib, anti-VEGF aptamer) which slowed vision loss compared to conventional 
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treatment such as laser coagulation, or photodynamic therapy, however Macugen® did 
not improve visual acuity in patients [5]. The next FDA-approved, anti-VEGF, agent for 
wet AMD was Lucentis® (ranibizumab, anti-VEGF monoclonal antibody Fab fragment), 
which until recently was the leading product in the market owing to its ability to improve 
visual acuity significantly in wet AMD patients. On the other hand, Avastin® 
(bevacizumab, anti-VEGF whole monoclonal antibody), which is officially approved for 
various forms of cancer, has been used off-label extensively by clinicians since it shows 
similar efficacy to Lucentis® and a single equivalent dose of Avastin® for wet AMD is 
actually 40 times less expensive than that of Lucentis® [6,7]. Recently in 2011, Eylea® 
(aflibercept, a recombinant fusion protein consisting of portions of human VEGF 
receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1) was 
approved for wet AMD and is currently the most promising anti-VEGF agent since it 
demonstrates better outcomes than the other anti-VEGF antibodies [8]. The current 
dosing regimen of the anti-VEGF antibodies is monthly by intravitreal injection, but this 
is very inconvenient for patients [9] and repeated injections introduce risk of infection, 
inflammation and hemorrhage [10]. Therefore, sustained release formulations are needed 
to reduce administration frequency for improved patient compliance and convenience and 
minimize the risks by maintaining the therapeutic concentration longer at the target site. 
PLGA is among the most commonly and extensively researched polymer 
biomaterials, and has been used in numerous FDA-approved medical devices for 
controlled release formulations due to its biodegradability, biocompatibility and ability to 
achieve desirable release kinetics [11]. Several forms of PLGA depots for controlled 
release of protein have been developed such as microspheres, nanoparticles, implants, 
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and films [12–15]. Among these different types of PLGA formulations, the PLGA 
implant has advantages over other forms namely in: high and easily controlled loading, 
high loading efficiency, minimally invasive injection, and anhydrous encapsulation of 
protein for additional stability. In terms of ocular delivery, there is a FDA-approved 
precedent: Ozurdex® is a PLGA implant for controlled release of dexamethasone into the 
eye [16]. In this study, therefore, PLGA implants were deemed a viable option and 
further investigated for controlled release of bevacizumab in the vitreous. 
Desirable attributes of the bevacizumab loaded implants are high loading of the 
antibodies due to the limit of intravitreal injection volume and near zero-order release 
profile to maintain effective antibody concentration in the vitreous. Release kinetics of 
osmotically active agents from hydrophobic polymer matrix depends on a number of 
factors including the excipient loading [17,18]. Therefore, loading of the antibodies has 
to be adjusted to obtain desired release kinetics as well. To stabilize encapsulated 
proteins, additional osmolytes such as salts, and sugars may be needed, but these will 
affect the release kinetics of antibodies as well. These stabilizing parameters were 
described in Chapter 3. To achieve desired release kinetics, in addition to adjusting the 
loading, coating “core implants” (monolithic implants investigated in Chapter 3) with 
pure polymer has been utilized to sustain release of highly loaded antibiotics [19,20], 
testosterone, estradiol-17β [21], and bovine serum albumin [22]. 
In this chapter, polymer coated (or referred to simply as “coated”) PLGA implants 
for anti-VEGF therapy were developed to achieve the desirable attributes with 
formulating anti-VEGF protein dosage forms. Several important elements were identified 
to achieve a formulation with desirable stability and controlled release of bevacizumab 
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from PLGA, namely: (a) developing a suitable PLGA coating method and optimizing it 
to achieve near zero-order and complete release (>80%); (b) incorporating a poorly 
soluble base to neutralize acids liberated from PLGA for protein stability combined with 
a PLGA of a suitable MW with end-capping to accomplish continuous release; (c) 
applying cryomilling for safely preparing protein powder for encapsulation; and (d) 
applying an anhydrous solvent extrusion technique to both stabilize the protein during 
encapsulation and to create cylindrical implants suitable for intravitreal injection. The 
studies below describe the formulation optimization that incorporate the above important 
elements, and the in vitro performance of the resulting coated PLGA millicylindrical 
implants for slow-release of stable bevacizumab. 
 
 Materials and Methods 
4.3.1 Materials 
Avastin®, commercial solution of bevacizumab, was purchased from the 
pharmacy and used within its shelf-life period. PLGA 50:50 (inherent viscosity = 0.64 
dL/g and Mw = 54.3 kDa, ester terminated) was purchased from LACTEL Absorbable 
Polymers (Birmingham, AL). Trehalose dihydrate (trehalose), MgCO3, guanidine 
hydrochloride, DL-dithiothreitol (DTT), ethylenediamine-tetraacetic acid (EDTA), 
Na2HPO4, NaH2PO4, anti-human IgG-alkaline phosphatase antibody produced in goat 
and p-nitrophenyl phosphate liquid substrate system (pNPP) were purchased from Sigma-
Aldrich Chemicals (St. Louis, MO). Tween 80 (10%), acetone, KH2PO4, K2HPO4, KCl, 
phosphate buffered saline (PBS), Amicon Ultra-15 Centrifugal Filter Units (10,000 
MWCO), silicone rubber tubing, and Coomassie plus reagent assay kit were purchased 
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from Fisher Scientific (Hanover Park, IL). Recombinant human vascular endothelial 
growth factor (VEGF) was a generous gift from Genentech. 
4.3.2 Preparation of bevacizumab powder 
The buffer of Avastin® solution containing bevacizumab and excipients was 
exchanged into 51 mM sodium phosphate buffer (pH 6.2) by using Amicon Centrifugal 
Filter Units (10,000 MWCO) to remove trehalose. Then, trehalose was added (weight of 
trehalose : weight of bevacizumab = 1.5 : 1) again and the solution was diluted with 51 
mM sodium phosphate buffer (pH 6.2) for the final bevacizumab concentration of 25 
mg/mL and lyophilized. The solid was then ground by CryoMill (Retsch, Germany) at 30 
Hz for 30 min and sieved through 90-μm screen (Newark Wize Wearing, Newark, NJ). 
4.3.3 Preparation of coated implants with bevacizumab  
The resulting bevacizumab powder was suspended into 50 % (w/w) PLGA 
solution in acetone with 3% (w/w) MgCO3 in a 2 mL centrifuge tube, then mixed and 
transferred into a 3 mL syringe. The suspension was extruded into silicone rubber tubing 
(I.D. = 0.8 mm), then dried at room temperature for 48 h followed by vacuum drying at 
40°C and -23 in. Hg vacuum for an additional 48 h. The final dried implants were 
obtained by removal of silicone tubing and were cut into segments of desired length for 
future use. For coated implants, the core implants were put back into silicone tubing and 
pure PLGA solution at various concentrations in acetone within a 3 mL syringe was 
extruded over the core implants to coat the surface and dried in vacuum oven at room 
temperature for 48 h and at 40°C for an additional 48 h. Then, silicone tubing was 
removed and the final coated implants were cut for the following experiments. 
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4.3.4  Measurement of bevacizumab loading in implants 
Implants (3-5 mg) were dissolved in 1 mL of acetone for 1 h and centrifuged to 
precipitate proteins. PLGA dissolved in supernatant was removed and the protein pellet 
was washed with acetone and centrifuged three times more to remove residual PLGA. 
The pellet was then air dried, reconstituted in 1 mL of PBST (phosphate buffered saline 
with 0.02 % Tween 80, pH 7.4) at 37°C overnight and analyzed by size-exclusion high-
performance liquid chromatography (SE-HPLC). The condition of SE-HPLC to quantify 
monomer and soluble aggregates was followed as previously described [23] with slight 
modifications, which included the injection volume of 50 µL and filtration of all samples 
through 0.45 µm filter. Extracted loading and loading efficiency were calculated by the 
following equations. 
Extracted	loading	ሺ%ሻ ൌ Weight	of	extracted	bevacizumabWeight	of	total	implant 	ൈ 100	% 
 
Loading	efficiency	ሺ%ሻ ൌ Extracted	loadingTheoretical	loading	ൈ 100	% 
4.3.5 In vitro release study of bevacizumab from implants 
Implants (0.5 - 2 cm long, 3 - 14 mg) were added in 1.5 mL centrifuge tubes with 
1 mL of PBST and incubated at 37°C without agitation, as agitation was found to cause 
insoluble aggregation of the antibody in the release media. The release medium was 
replaced with fresh medium at each time point. The amount of released bevacizumab at 
each time point was measured by SE-HPLC and calculated as percentage of the released 
amount out of the extracted loading of soluble bevacizumab. In certain instances, the 
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release media was also analyzed for protein structure and immunoreactivity, as described 
below. 
4.3.6 Evaluation of residual bevacizumab in implants 
At the end of release study, the remaining bevacizumab was extracted by the same 
procedure used to measure protein loading after lyophilizing the remaining polymer. The 
protein pellet was then reconstituted in PBST and incubated at 37°C overnight to 
determine the soluble fraction of the protein that remained in the polymer. After 
centrifugation, the supernatant was collected and the remaining insoluble precipitates 
were dissolved in denaturing solvent (6 M guanidine hydrochloride/1 mM EDTA) at 
37°C for 1 h to determine non-covalent protein aggregates. After centrifuging and 
collecting supernatant, the remaining insoluble precipitates were dissolved in 
denaturing/reducing solvent (6 M guanidine hydrochloride /1 mM EDTA/10 mM DTT) 
to measure covalent protein aggregates formed by disulfide bonds. Concentration of 
protein aggregates in each step was measured by Coomassie plus protein assay. All 
measurements were performed in triplicate and bevacizumab standards were dissolved in 
the same solvent used for each analysis. 
4.3.7 Enzyme linked immunosorbent assay (ELISA) 
ELISA was performed to determine immunoreactivity of the released 
bevacizumab as described previously [24] with some modifications. Briefly, 96-well 
ELISA microplates were pre-coated with 50 μl of VEGF (0.5 μg/mL) solution in PBS 
(phosphate buffered saline, pH 7.4) at 4°C overnight. After washing with 350 μl of PBS 
four times, 100 μl of PBS containing 1 % BSA (bovine serum albumin) was added for 
blocking and incubated at room temperature for 2 h. After washing, 50 μl of bevacizumab 
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standards (0 ~ 2.56 μg/mL) and samples diluted in PBST containing 1 % BSA were 
added into each well and incubated at room temperature for 1 h. After washing, 50 μl of 
secondary antibody (alkaline phosphatase conjugated goat anti-human IgG) was added at 
1: 1000 dilution in PBST containing 1 % BSA into each well and incubated for another 1 
h. Detection was carried out by adding 50 μl of pNPP after washing. Color development 
was monitored with a plate reader (Dynex MRX II, Richfield, MN) every 10 min at 405 
nm until R-squared value of the standard curve started decreasing. 
4.3.8 Circular dichroism (CD) 
CD was performed with Jasco J-815 CD spectrometer equipped with Jasco 
temperature controller (CDF-426S/15) and Peltier cell at 25 °C. The samples were diluted 
or buffer-exchanged into 51 mM sodium phosphate buffer (pH 6.2) and concentrated by 
using Amicon Centrifugal Filter Units (10,000 MWCO), so the final concentration 
ranged from 0.05 to 0.5 mg/mL for far UV measurements. The samples were measured in 
quartz cuvettes (Hellma) with a path length of 1 mm. The spectra were collected in 
continuous mode at a speed of 50 nm/min, bandwidth of 1 nm and a data integration time 
of 1sec and were averaged from 10 scans. The spectrum of blank 51 mM sodium 
phosphate buffer (pH 6.2) was subtracted from each spectrum by using the Jasco spectra 
manager software (Version 2.1). The raw data was converted to mean residue ellipticity 
(MRE) using the following equation: 
ሾࣂሿ࢓࢘࢝,ࣅ ൌ ࡹࡾࢃൈ ࣂࣅ૚૙ ൈ ࢊ ൈ ࢉ 
where is the θλ observed ellipticity in degree at wavelength λ, d is the path length in cm, c 
is the concentration in g/mL, and mean residue weight (MRW) in g/mol is 113 for 
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bevacizumab. The resulting CD spectra were smoothed using SigmaPlot software 
(Version 12.0, Systat Software, Inc.).  
4.3.9 Confocal microscopy 
The distribution of protein powder and PLGA coating in the coated implants was 
visualized using confocal microscopy. BSA labeled with Alexa Fluor® 488 (Thermo 
Fisher Scientific, Waltham, MA) was used as a fluorescent model protein. Regular BSA 
including 5 % of the fluorescent BSA was loaded at 10 % with trehalose and MgCO3 into 
core implants as described before. To visualize and distinguish the PLGA coating from 
the fluorescent protein, Cyanine5 carboxylic acid dyes (Cy5, Lumiprobe, Hallandale 
Beach, FL) were dissolved at 10 µg/mL in PLGA/acetone solution, and the core implants 
were coated with the Cy5/PLGA solution as previously described. The dried implants 
were cut for cross-sectional images and placed on a clean glass slide. A clean glass cover 
slide was placed over the implant slices. To visualize lateral surface of implants, the dried 
or lyophilized implants from in vitro release study were placed on a glass slide. Samples 
were imaged using a confocal microscope (Nikon A1 Spectral Confocal Microscope) 
with excitation/emission wavelengths of 488/525 nm for the BSA labeled with Alexa 
Fluor® 488 and 640/700 nm for the Cy5 in PLGA coating. 
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 Results and Discussion 
4.4.1 Coated implants with pure PLGA for higher loading and improved 
continuous release 
The strategy of reducing trehalose in the drug powder shown in the previous 
chapter had limitations for higher loading of bevacizumab, sustained release, and mAb 
stability. Therefore, a coating strategy was tested as a next step because they have been 
previously employed for high drug loading and sustained release in hydrophobic polymer 
implants [19–22]. As a coating method, simply extruding pure PLGA over the core 
implants in silicone tubing was used and the degree of coating was controlled by PLGA 
concentration in coating solution. Since the loading of bevacizumab needs to be high 
after coating, only 10 and 15 % loaded core implants were coated and tested. The 
extracted loadings of bevacizumab in uncoated, and 10, 30 and 50 % PLGA coated 
implants were 9.2, 9.0, 8.2, and 7.6 %, respectively. In addition, the diameters of 
uncoated, and 10, 30 and 50 % PLGA coated implants were 0.64, 0.64, 0.75, and 0.88 
mm, respectively (Table 4.1). The extracted loadings of bevacizumab in the coated 
implants were lower than that of the uncoated implants, and a higher PLGA concentration 
in the coating solution resulted in lower extracted loading since the coating added more 
PLGA mass into the implants. Also as expected, a higher PLGA concentration (30 and 
50 %) in the coating polymer solution resulted in thicker diameters of implants.  
As a core, 10 % bevacizumab loaded implants with 1.5:1 powder were tested to 
determine how PLGA concentration in coating affected the release profile. Coated 
implants with 10 % PLGA showed slower release rate than the core implant and the 
implants coated with 30 and 50 % PLGA released bevacizumab even slower than the 
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10 % coated one and showed near zero-order release profiles for 6 weeks. The initial 
burst release on day 1 reduced from 51 % in uncoated implants to 14 % in 10 % PLGA 
coated ones, and 5.1 and 6.7 % in 30 and 50 % PLGA coated ones, respectively, Total 
cumulative releases from the uncoated and the 10, 30 and 50 % PLGA coated implants 
were 97, 92, 89, and 82 %, respectively (Figure 4.1 A). The implants coated with higher 
PLGA concentration than 50 % were not able to be tested because PLGA solution was 
too viscous to extrude over the core implants.  
The release from the uncoated implants loaded with 10 % bevacizumab and 1.5:1 
w/w trehalose : protein powder was fast and likely dominated by pure diffusion-through-
channel since the drug particles above the percolation threshold were interconnected 
rapidly. By coating the lateral surface-wall of core implants, fast release of bevacizumab 
located near the surface was expected to occur primarily through the both open ends, thus 
resulting in lower initial burst release. The proteins located deeply into the middle of 
coated implants have much longer distance to the surface of both ends than that in 
uncoated implants whose maximum is only the radius of the implants. Hence, less 
complete channels from a drug particle to the surface in coated implants were formed 
even above the percolation threshold in core implants and resulted in low initial burst 
release and slower following release driven by slow formation of osmotic pressure-
induced channels. Release rates of 30 and 50 % PLGA coated implants were similar 
during the whole release study period whereas release was faster in 10 % PLGA coated 
implants. Thus, 10 % PLGA coating was likely not thick enough to effectively coat the 
core implants completely during release, while PLGA at 30 % concentration or higher 
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coat the core implants sufficiently to prevent the release through the side walls before 
polymer mass loss occurs.  
However, 50 % PLGA coated implants with 15 % bevacizumab loading of 1.5:1 
powder still showed very high initial burst release (81 %) and near complete release after 
day 7. At this total powder loading (41.7 %) in core implants, most of the drug particles 
are thought to be closely interconnected, thus enabling the formation of water channels 
through the interconnected particles from both open ends rapidly once the implants are 
put in release medium. The coated implants with 10 % core loading of bevacizumab with 
2.4:1 powder was also tested as a control. As expected, the initial burst release on day 1 
was higher (24 %) than that (6.7 %) of the corresponding implant with 1.5:1 powder due 
to higher loading of osmotically active trehalose in core implants (Figure 4.1 B). By 
coating implants with pure PLGA, therefore, 30 and 50 % PLGA coated implants with 
10 % bevacizumab loading of 1.5:1 powder were the best formulations among all the 
tested formulations for higher loading (8.2 and 7.6 %), more sustained release, and higher 
total cumulative release (89 and 82 %). The major residual proteins in polymer were non-
covalent aggregates, which were 7.8 and 8.9 %, and total recoveries were 98 and 92 %, 
respectively (Table 4.2).  It is important to note that a small difference in recovery and 
complete release was observed for the two different optimized coating conditions. It is 
possible that the thinner coating (from 30% polymer concentration), which was also 
sufficient to maintain the release, was able to reduce the diffusion barrier to water-soluble 
acids relative to the thicker coating (50%), slightly increase the microclimate pH to 
reduce aggregation and hydrolysis of the protein. Future studies will be aimed at 
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discerning these more subtle variations and also increasing duration of the release by 
increasing lactic content in the polymer. 
4.4.2 Geometric analysis of powder distribution and PLGA coating 
To visualize distribution of protein powder and PLGA coating on the cross-
section of coated implants, confocal microscopy was performed.  A commercial 
fluorescent (Alexa Fluor® 488) BSA was loaded into the core implants instead of 
bevacizumab to ensure high intensity of fluorescence. The powder with the green 
fluorescent BSA was homogeneously distributed on the cross-section of core implants, 
and a PLGA coating containing Cy5 dyes surrounded the core implants well in the both 
30 % and 50 % PLGA coated implants (Figure 4.2). It was observed that the thickness of 
a PLGA coating was not consistent through the peripheral region and the PLGA coating 
of some parts invaded the region of core implants. 
4.4.3 Stability of bevacizumab extracted and released from coated implants 
To investigate the stability of released bevacizumab from these optimized 
implants, monomer content, immunoreactivity and conformational stability in secondary 
structure were evaluated via SE-HPLC, ELISA and CD. Intact bevacizumab originally 
shows a small dimer peak in size-exclusion chromatogram and the monomer content 
calculated by the following equation, 	
Monomer	content	ሺ%ሻ ൌ AUC	of	a	monomer	peakAUC	of	total	peaks 	ൈ 100	% 
is dependent on the concentration of bevacizumab. Released proteins from the optimized 
formulations had a bit less monomer content than that of the corresponding concentration 
of intact bevacizumab, but it was maintained above 90 % during the whole period (Figure 
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4.3 A). Until 3-4 weeks of release, the monomer content decreased and slightly increased 
after then. It is speculated that formation of soluble dimers or oligomers from monomers 
resulted in the early decrease in monomer content and consumption of the soluble 
aggregates as nuclei for growth of higher order insoluble aggregates trapped in polymer 
caused the later increase in monomer content.  
The immunoreactivity of extracted and released proteins from the coated implants 
was also measured to evaluate the binding activity against VEGF, which is a target 
antigen (Figure 4.3 B). It was calculated by the following equation, 
Immunoreactivity	ሺ%ሻ ൌ Concentration	from	ELISAConcentration	from	SE െ HPLC	ൈ 100	% 
, and measured at 115 and 102 % for extracts from 30 and 50 % PLGA coated implants, 
which means preparation of implants and extraction process did not decrease 
immunoreactivity of bevacizumab. For the release samples, it was maintained between 83 
and 112 % for 30 % PLGA coated ones and between 89 and 105 % for 50 % PLGA 
coated ones until day 28. On day 42, it slightly decreased to 74 and 79 %, respectively. 
 Additionally, the far-UV CD spectra showed high conformational stability in the 
secondary structure of bevacizumab from powders, extracts, and release samples from 
30 % (Figure 4.4 A) and 50 % (Figure 4.4 B) PLGA coated implants. Immunoglobulin 
G1 (IgG1), a subclass of bevacizumab, is known to have significant β-sheet structure 
characterized by broad negative peak at 218 nm in its far-UV CD spectrum [25], and all 
the spectra from each bevacizumab sample indicated insignificant changes in the 
secondary structure at the various stages. Therefore, it is concluded that released soluble 
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bevacizumab from the coated implants in a sustained manner also maintained the 
monomer content, immunoreactivity and secondary structure for 6 weeks. 
4.4.4 Release kinetics of bevacizumab from coated implants of different lengths 
The duration of bevacizumab release from the implants needs to be extended to 
longer than 6 weeks since at least 3-month releasing formulations are desired to reduce 
administration frequency of bevacizumab. Assuming complete insulation of the lateral 
surface of implants by the PLGA coating, the protein release will be slower and duration 
of release may become longer since the area of both open ends of the coated implants is 
constant regardless of the length of implants. To test this hypothesis, an in vitro study 
with the 30 % PLGA coated implants of three different lengths (0.5, 1 and 2 cm-long) 
was performed. However, except for the initial day 1-7 releases, the overall release rates 
of all the three implants were similar unlike our expectation (Figure 4.5). Therefore, the 
assumption of complete insulation of lateral surface might have been incorrect and the 
protein may still be released through the lateral surface of implants despite the polymer 
coating. In order to observe this, the coated implants with the fluorescent BSA and 
Cy5/PLGA coating from select time points of in vitro release study were visualized by 
confocal microscopy (Figure 4.6). As shown in Figure 4.6 A and B representing different 
lateral surface of the same piece of implant, the PLGA coating is not completely 
surrounding the core implant, therefore, the protein can be released though this uncoated 
part of the lateral surface. In addition, from the lateral surface images after day1, 3, 7 and 
14 release (Figure 4.6 C, D, E and F), it is observed that pores are formed from the 
beginning of release study and become bigger, presumably due to swelling of the 
implants, along the release time. Therefore, the protein can be released through the pores 
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formed on the lateral surface of implants as well. This release phenomenon of proteins 
through the lateral surface of implants was observed in the cross-sectional images of the 
implants from day7 (Figure 4.6 G) and day14 (Figure 4.6 H) release. In these images, the 
fluorescent proteins are located more in the center of implants, and less in the peripheral 
region. Especially in the peripheral region near the surface of less coated part, more 
proteins seem to be released out compared to other peripheral regions. To slow down the 
release and extend the duration of release, a new method of coating procedure and/or a 
new coating material should be evaluated. 
 
 Conclusion 
In this study, bevacizumab was loaded into coated PLGA implants and evaluated 
to develop sustained release formulation to reduce intravitreal administration frequency. 
By coating the core implants with PLGA, high loading (7.6-8.2 %, w/w) and continuous, 
near zero-order release over 6 weeks were achieved without a high initial burst release.  
Co-encapsulating trehalose and MgCO3 as stabilizers also helped to achieve high total 
cumulative release (81.7-89.0 %). Bevacizumab released from these coated implants 
maintained the monomer content well above 90 % as well as its immunoreactivity, and 
secondary structure during the 6-week release period. It was observed by confocal 
microscopy that the proteins are also released through the lateral surface of the coated 
implants due to the non-uniform PLGA coating. Future work is directed towards 
evaluating the in vivo release kinetics and efficacy of the implants and improving the 
formulations to extend the duration of release to facilitate 3 month intervals between 
intravitreal injections. Finally, owing to the structural similarity of therapeutic 
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monoclonal antibodies, the coated PLGA implants, with the addition of appropriate 
disaccharides and antacids as stabilizers, have the potential to serve as delivery platforms 
for sustained release of other therapeutic monoclonal antibodies as well. Therefore, 
formulating other antibody drugs, which need sustained local delivery, with the described 
platform is a logical next step to pursue.  
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 Table 4.1: Extracted loading and diameter of uncoated and coated implants.  
Trehalose: 
bevacizumab 
in powder 
(w/w) 
PLGA concentration in 
coating (%, w/w) 
Theoretical 
loading in core 
implants (%) 
Extracted 
loading (%)a 
Diameter 
(mm)a 
1.5:1 
Uncoated 
10 
9.2 ± 0.2  0.64 ± 0.02 
10 9.0 ± 0.7 0.64 ± 0.01 
30 8.2 ± 1.1 0.75 ± 0.01 
50 7.6 ± 0.4 0.88 ± 0.01 
50 15 10.8 ± 0.3 N.D.   
2.4:1 50 10 7.6 ± 0.8 N.D. 
a Data reported as mean ± SD, n=3.  N.D. = not determined. 
 
 
 
Table 4.2: Mass balance of bevacizumab from in vitro release study of the coated 
implants prepared with 1.5:1 w/w trehalose : bevacizumab powder. 
PLGA 
concentration 
in coating 
(%, w/w) 
Cumulative 
release (%) 
Soluble 
residue (%)
Non-covalent 
aggregate (%) 
Covalent 
aggregate (%) 
Recovery 
(%) 
30 89 ± 4 0 7.8 ± 0.4 0.9 ± 0.3 98 ± 4 
50 82 ± 8 0 8.9 ± 4.2 1.4 ± 1.6 92 ± 9 
Data reported as mean ± SD, n=3 
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Figure 4.1: Release kinetics of bevacizumab from uncoated (▼) and coated (∆, ○, ●, ■, 
♦) implants. Concentrations of PLGA solution for coating were 10 % (∆), 30 % (●), and 
50 % (○) for the core implants prepared with 10 % initial theoretical loading of buffer-
exchanged bevacizumab powder with 1.5 to 1 w/w trehalose : bevacizumab (A). With 
50 % PLGA in coating, release kinetics of different core implants loaded with 15% 
bevacizumab of the 1.5:1 powder (■), and loaded with 10 % bevacizumab of the original 
Avastin in the powder (♦) were compared to that of implants loaded with 10 % 
bevacizumab of the 1.5:1 powder (○) (B). Symbols represent mean ± SD, n=3. 
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Figure 4.2: Cross-sectional images of 30 % (A) and 50 % (B) PLGA coated implants 
observed by confocal microscopy. The green and the purple indicate protein powder and 
PLGA coating, respectively. 
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Figure 4.3: Monomer content (A) and immunoreactivity (B) of released bevacizumab 
from implants coated with 30 % w/w PLGA (●) and 50 %w/w PLGA (○). Data are mean 
± SD, n=3. 
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Figure 4.4: CD spectra of bevacizumab from Avastin® solution (control), 1:5 powder, 
extracts, and release samples at specific days of 30 % (A) and 50 % (B) PLGA coated 
implants. Concentration of the protein measured by SE-HPLC was used to normalize all 
data. 
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Figure 4.5: Release kinetics of bevacizumab from implants of different lengths (●: 0.5 
cm, ○: 1 cm, ▼: 2 cm) prepared with 10 % initial theoretical loading of buffer-
exchanged bevacizumab powder with 1.5 to 1 w/w trehalose:bevacizumab in the core 
implants and coated with 30 % PLGA. Symbols represent mean ± SD, n=3. 
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Figure 4.6: Distribution of Cy5/PLGA coating (purple) and fluorescent protein powder 
(green) on the lateral surface and cross-sections of coated implants during in vitro 
release study visualized by confocal microscopy. A and B represent different lateral 
surface of the same implant before release study. C, D, E and F represent lateral surface 
of the coated implant after day1, 3, 7 and 14 release, respectively. G and H demonstrate 
cross-sections of the coated implants after day 7 and 14 release. The dotted white lines 
indicate borders of the implant cross-sections.  
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Chapter 5: Conclusions, Significance and Future Work 
The work presented in this dissertation takes aim at three requirements pertaining 
to successfully developing poly(lactic-co-glycolic acid) (PLGA) depot formulations of 
bevacizumab (or its Fab fragment) to reduce administration frequency for improved 
patient compliance and convenience, and to minimize risks of intravitreal injection for 
wet age-related macular degeneration (AMD): i) high w/w loading and loading efficiency 
of the antibodies due to the limited injection volume into the vitreous and improving the 
cost-effectiveness, ii) near zero-order and complete release of the antibodies for 3 
months, and iii) minimal instability of the released antibodies for high efficacy and low 
immunogenicity.  
Active self-encapsulation technology and utilizing poorly soluble basic salts to 
neutralize deleterious low pH in PLGA matrices were previously developed in our lab to 
achieve the above goals for other protein drugs [1,2]. Therefore, in Chapter 2, we applied 
those technologies to develop active self-encapsulating PLGA microspheres for the anti-
VEGF antibodies. The previously utilized trapping agent for lysozyme [3], high 
molecular weight dextran sulfate (HDS) was employed since the HDS negative charge 
can entrap the positively charged antibodies. ZnCO3 was co-encapsulated as an antacid 
and this resulted in continuous release of the immunoreactive antibodies for 56 days. But, 
w/w loading and loading efficiency were too low. Although several parameters (e.g. 
ZnCO3 and HDS content, loading solution pH, and protein concentration in loading 
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solution) were adjusted, both loading (w/w) and loading efficiency were not significantly 
improved.  
To increase the low loading and encapsulation efficiency observed in Chapter 2, 
in Chapter 3 PLGA millicylindrical implants were investigated. High w/w loading can be 
achieved using an anhydrous encapsulation procedure for proteins. Co-incorporation of 
trehalose afforded stabilization of the proteins against aggregation during powder 
preparation, but also contributed to faster release of the proteins due to its osmotic 
activity. Therefore, the ratio of trehalose and bevacizumab was optimized to sustain 
release of the protein while maintaining the stabilizing effect. For the desirable release 
rate, the loading of bevacizumab needed to be reduced to 3-6 %, but the total cumulative 
release was also reduced, indicating less than desired protein stability. The slower and 
less complete release from the implants with lower loading of water soluble and 
osmotically active trehalose can be explained by the percolation theory and an osmotic 
pressure-induced release mechanism. At the low loading below the percolation threshold, 
drug particles including substantial amount of osmotically active trehalose are dissolved 
and form isolated water pores after water start partitioning into polymer matrix. High 
osmotic pressure created in the water pores induces imbibition of more water, 
consequently, the water pores are ruptured and microcracks are formed. Subsequently, 
the microcracks interconnect the isolated water pores and form water channels to the 
surface of implant, thus enabling drug release. In this case, formation of the complete 
water channels to the surface is a slow process, thus a rate limiting step for release. By 
the slow process, distribution of the dissolved antacids through the polymer matrix and 
removal of acid byproducts from the matrix are also delayed, thus resulting in more 
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protein aggregates and less complete release. Therefore, the critical key parameter to 
control release of water soluble drugs from the hydrophobic polymer matrix is the 
loading of osmotically active components. 
To increase the loading and the total cumulative release, and to enhance the 
release kinetics simultaneously, in Chapter 4 a simple coating technique with pure 
polymer over the core implant was developed. The optimized formulation released 
bevacizumab for 6 weeks with near zero-order release kinetics and the total cumulative 
release of 89 %. Stability of the released antibodies was analyzed in various aspects and it 
was shown that colloidal stability, immunoreactivity, and secondary structures were well-
preserved during the release period. Therefore, most desired characteristics of the ideal 
formulations for sustained delivery of the anti-VEGF antibodies were obtained by the 
strategy of coated implant, namely: (a) high loading capacity (w/w) and loading 
efficiency; (b) near zero-order release kinetics with high total cumulative release; and (c) 
minimal instability of encapsulated and released antibodies. One unmet characteristic is 
duration of release which was ultimately aimed at 3 months or longer. Assuming 
complete insulation of the lateral surface of coated implants, duration of release should be 
controlled by the length of implant, but it was not dependent on the length. It was 
observed that protein was also released through the lateral surface of coated implants, 
since the coating was not uniform on all sides and pores were formed on the lateral 
PLGA coating after release study started. Therefore, future studies are directed toward 
discovering an appropriate coating material  and developing a new coating technique for 
more complete insulation of the lateral surface. Then, evaluating in vivo release behavior 
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and efficacy in animals is also needed to understand the clinical potential of our new 
approach.  
Current strategies for sustained delivery of anti-VEGF antibodies discussed in 
Chapter 1 have their own pros and cons as an ideal formulation with the desired 
characteristics and the incompleteness hinders their clinical development. By addressing 
the issue encountered in the strategy of coated implant, this approach may have a great 
potential for clinical development of a sustained anti-VEGF antibody release formulation. 
In addition, the structural similarity of monoclonal antibodies enables formulating other 
antibody drugs, which need sustained local delivery, in this delivery platform. Also, with 
an appropriate stabilizing strategy, this sustained delivery approach can be broadly 
utilized for any water soluble drugs due to its generalizable nature. 
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Appendix A: PLGA implants of recombinant adeno-associated 
virus for gene therapy 
A.1 Introduction 
Gene therapy has been tremendously researched over the last few decades and 
will be an important treatment option for several genetic and acquired diseases because it 
is aimed at treating or eliminating the cause of diseases, whereas most current drugs are 
designed to treat the symptoms [1,2]. In order to deliver “therapeutic genes” into the 
target cells, enormous research efforts in the area of gene delivery vectors have been 
performed worldwide. There are two categories of gene delivery vector for gene therapy: 
non-viral vectors and viral vectors [3]. Viral vectors have an obvious advantage in gene 
transfer efficiency over non-viral vectors since viruses have a natural capability of gene 
transfer to host target cells; however, immunogenicity of viral vectors has been a major 
safety issue for clinical development [4]. Recombinant adeno-associated virus (AAV) 
vector is among the various viral vector species, and has several promising properties for 
gene therapy: non-pathogenicity, capability to transduce both dividing and non-dividing 
cells, and capability of long-term transgene expression [5]. Although AAV has shown 
relatively low immunogenicity compared to other viral vector species, a major challenge 
that prevent the clinical use of AAV in patients is humoral immune responses against the 
AAV capsid proteins or the transgenic proteins [6]. To overcome this issue, several 
strategies have been used, including a high dose injection, the use of alternative routes of 
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administration, the use of alternative serotypes, a transient host immunosuppression, the 
use of AAV capsid decoys, and modification of capsid proteins/epitopes [7–10]. 
However, all these strategies have been tested in preclinical models, so limited 
information is available in patients and many of these approaches will have to be adjusted 
to each individual due to the variability of the AAV immune response. Considering these 
complexities, new universal strategies are necessary to exploit AAV for clinical gene 
therapy. 
As a new approach, a controlled release technology might be a probable strategy 
to overcome the issues for clinical use of AAV. Controlled release systems have been 
developed to control the temporal and spatial exposure of therapeutics to a defined target 
as a means to protect the drugs from physiological degradation and unwanted side effects 
and improve patient compliance [11]. AAV needs to reside only in the target area, 
however, injections may cause leakage of AAV to systemic circulation, and this may 
result in more humoral immune response against the administered AAV. In this chapter, 
potential of poly(lactic-co-glycolic acid) (PLGA) millicylindrical implants was 
investigated for controlled release of AAV to address the issue. In the previous chapters, 
PLGA implant has proved its high potential for controlled release of proteins with 
minimal instability. AAV capsid is also proteinaceous, so it is expected that PLGA 
implants can be formulated for an optimal controlled release system of AAV. 
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A.2 Materials and Methods 
A.2.1 Materials 
Pre-made AAV2 was purchased from Vector BioLabs (Malvern, PA). AAV clone 
C4 was constructed and kindly provided by Dr. David Schaffer (University of California 
at Berkeley, CA). PLGA 50:50 (inherent viscosity = 0.64 dL/g and Mw = 54.3 kDa, ester 
terminated) was purchased from LACTEL Absorbable Polymers (Birmingham, AL). 
Trehalose dihydrate (trehalose), ethylenediaminetetraacetic acid (EDTA) and bovine 
serum albumin (BSA) were purchased from Sigma-Aldrich Chemicals (St. Louis, MO). 
Magnesium carbonate (MgCO3), magnesium hexahydrate (MgCl2), sodium chloride 
(NaCl), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), Tween 80 (10%), 
acetone, phosphate buffered saline (PBS), silicone rubber tubing, and Coomassie plus 
reagent assay kit were purchased from Fisher Scientific (Hanover Park, IL). PD SpinTrap 
G-25 desalting column was purchased from GE Healthcare Life Sciences (Pittsburgh, 
PA). ONE-Glo™ Luciferase Assay System was purchased from Promega (Madison, WI). 
HEK-293 cell was a generous gift from Dr. Mark Cohen (University of Michigan at Ann 
Arbor, MI).  
A.2.2 Cation-exchange high-performance liquid chromatography (CEX-HPLC) 
A TSKgel SP-NPR (Tosoh Bioscience, Japan) cation-exchange column was used 
to quantify AAV samples in HPLC. The column was equilibrated at a flow-rate of 1 
mL/min on a Waters Agilent HPLC system (Waters, Milford, MA) equipped with a PDA 
detector. Empower® 3 Software (Waters) was used to integrate peak areas. After sample 
loading, the column was washed for 1 min with equilibration buffer (100 mM NaCl, 50 
mM HEPES, 1 mM EDTA, 5 mM MgCl2, pH 7.5) followed by a linear gradient from 100 
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to 500 mM NaCl in 50 mM HEPES, 1 mM EDTA, 5 mM MgCl2, pH 7.5. Area under 
curve (AUC) of the eluted peak was quantitated at 280 nm (Figure SA.1). The column 
was cleaned after running every sample set with a 0.6-ml injection of 0.5 M NaOH. 
A.2.3 Preparation of AAV powder 
The buffer (PBS with 0.001 % Tween 20 or PBS with 5 % glycerol) of AAV 
solution was exchanged into HEPES buffered saline (HBS, 20 mM HEPES, 130 mM  
NaCl, pH 7.4) with 5 mM MgCl2 and 0.02 % Tween 80 using a PD SpinTrap G-25 
desalting column. Then, trehalose and BSA were added at 10 mg/mL and 15 mg/mL, 
respectively, and the solution was lyophilized. The lyophilized solid was then ground 
using a spatula to form as fine powder as possible.  
A.2.4 Preparation of PLGA implant with AAV powder  
The resulting AAV powder was suspended into 50 % (w/w) PLGA solution in 
acetone with 3% (w/w) MgCO3 in a 2 mL centrifuge tube, then mixed and transferred 
into a 3 mL syringe. The suspension was extruded into silicone rubber tubing (I.D. = 0.8 
mm), then dried at room temperature for 48 h followed by vacuum drying at 40°C and -
23 in. Hg vacuum for an additional 48 h. The final dried implants were obtained by 
removal of silicone tubing and were cut into segments of desired length for future use.  
A.2.5  Measurement of AAV and BSA loading in implants 
Implants (2-5 mg) were dissolved in 1 mL of acetone for 1 h and centrifuged to 
precipitate the AAV/BSA powder. PLGA dissolved in supernatant was removed and the 
protein pellet was washed with acetone and centrifuged three times more to remove 
residual PLGA. The pellet was then air dried, reconstituted in 0.15 mL of HBS with 5 
mM MgCl2 and 0.02 % Tween 80 at 37°C overnight and analyzed by CEX-HPLC for 
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AAV and Coomassie plus reagent for BSA. Loading efficiency of AAV was calculated 
by the following equation. 
Loading	efficiency	ሺ%ሻ ൌ AUC	of	AAV	in	extractAUC	of	AAV	in	powder	ൈ 100	% 
 
Extracted loading and loading efficiency of BSA were calculated by the following 
equations. 
Extracted	loading	ሺ%ሻ ൌ Weight	of	extracted	BSAWeight	of	total	implant 	ൈ 100	% 
 
Loading	efficiency	ሺ%ሻ ൌ Extracted	loadingTheoretical	loading	ൈ 100	% 
 
A.2.6 In vitro release study of AAV and BSA from implants 
Implants (~ 5 mg) were added in 1.5 mL centrifuge tubes with 0.12 mL of HBS 
with 5 mM MgCl2 and 0.02 % Tween 80 and incubated at 37°C. The release medium was 
replaced with fresh medium at each time point. The amount of released AAV and BSA at 
each time point was measured by CEX-HPLC and Coomassie plus reagent, and 
calculated as percentage of the released amount out of the extracted loading of AAV and 
BSA.  
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A.2.7 Cell culture 
HEK-293 cells were kindly provided by Dr. Mark Cohen (University of Michigan 
at Ann Arbor, MI) and cultured in Dulbecco’s modified Eagle’s medium (Thermo Fisher 
Scientific, Waltham, MA) at 37°C and 5 % CO2. The medium was supplemented with 
10 % fetal bovine serum (Thermo Fisher Scientific) and 1 % penicillin/streptomycin 
(Thermo Fisher Scientific). 
A.2.8 Luciferase assay 
Luciferase assay was performed using a ONE-Glo™ Luciferase Assay System 
according to the manufacturer’s manual. HEK-293 cells were seeded in a 96-well clear 
bottom white plate at a density of 15000 cells in 100 µL of media per well. Phenol red-
free medium was used for luciferase assay because phenol red affects luminescence. The 
next day, 10 µL of the known concentration of AAV as standards and the samples were 
added into each well in triplicate. The concentration of standards was expressed as 
genomic multiplicity of infection (MOI) which is the ratio of vector genome of AAV to 
the number of cells. After 24 h, the equal volume of luciferase assay reagent to the media 
was added and the plate was read on SpectraMax M3 (Molecular Devices, Sunnyvale, 
CA). The MOI of samples was calculated in reference to a standard curve (Figure SA.2). 
 
A.3 Results and Discussion 
A.3.1 Finding a proper release buffer for AAV stability 
AAV is prone to aggregate easily at high concentration in aqueous buffer, so 
efforts to formulate AAV with stabilizers have been made to prevent aggregation [12–
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14]. To test in vitro release kinetics of AAV from PLGA implants, a proper release 
medium is needed to avoid artifacts caused by aggregation of AAV. First, a known 
concentration of AAV was incubated in PBS at 37°C and run in CEX-HPLC at select 
time points to compare AUC of AAV to the initial one. The relative AUC of AAV 
decreased to 20 % after day 14 and 6 % after day 28, and no AAV was detected after day 
63 (Figure A.1). Therefore, PBS is not a good release medium for in vitro release study 
of AAV because it will exhibit less AAV release than actually released. There was a 
report utilizing divalent cations to stabilize AAV in aqueous buffer [15]. Accordingly, 5 
mM MgCl2 was tested as a stabilizer in release buffer. Magnesium, however, forms 
insoluble precipitates when mixed with phosphate, therefore, HBS was used instead of 
PBS. Also, 0.02 % Tween 80 was co-added with the expectation of its anti-aggregating 
property for proteins [16–19]. In this release buffer, the relative AUC of AAV was 88 % 
after day 14, 89 % after day 28, and 64 % after day 63 compared to the initial AUC 
(Figure A.1). Therefore, this buffer was used for all the experiments in this study (e.g. the 
solution to lyophilize AAV, and the release medium).  
A.3.2 Evaluation of AAV loaded PLGA implants 
To prepare PLGA implants, water-soluble drugs to be encapsulated need to be 
lyophilized into powders, so the powders are suspended in PLGA/organic solvent 
solution and the implants hardened by evaporating the organic solvent [20]. To achieve 
controlled release of encapsulated drugs, the volumetric loading of drug powders needs to 
be above a certain level [21,22]. However, the mass of feasible amount of AAV particles 
is too small for powder preparation. In order to increase the volumetric loading, BSA was 
co-lyophilized with AAV as a bulk excipient and 1.5 times as much trehalose as BSA 
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was also added to stabilize BSA as described in Chapter 3 (Table A.1). Along with the 
lyophilized powders of AAV, 3 % MgCO3 was also added into PLGA implants (Table 
A.2) to neutralize PLGA acid byproducts which induce low pH and is deleterious to the 
encapsulated proteins [23]. The AAV powder was extracted from the implant using 
acetone and dissolved in the release buffer to measure extracted loading of AAV and 
BSA. The extracted loading efficiency of AAV was analyzed by CEX-HPLC and was 78 
± 14 % (mean ± SD, n=3) and the extracted w/w loading and loading efficiency of BSA 
measured by Coomassie protein assay were 3.7 ± 0.3 % and 99 ± 8 % (mean ± SD, n=3) 
respectively. The implants were incubated in the release buffer (HBS with 5 mM MgCl2 
and 0.02 % Tween 80) at 37°C for in vitro release study. The implant demonstrated near 
zero-order release of AAV for 3 weeks and total cumulative release normalized to the 
extracted loading was 94 % (Figure A.2 A). Release of BSA followed first-order kinetics 
for 4 weeks and total cumulative release was 105 % (Figure A.2 B). Therefore, PLGA 
implant can serve as a sustained release formulation of AAV and can be further 
optimized to extend the duration of release. It is thought that AAV release kinetics should 
follow the BSA release, but the differences in release kinetics and duration of release 
need to be further investigated.  
A.3.3 Infectivity of AAV loaded in PLGA implants 
It was demonstrated that AAV can be released from PLGA implant in a sustained 
manner, but infectivity of AAV also needs to be maintained in PLGA implant and after 
release. Therefore, AAV clone C4 encoding a firefly luciferase as a reporter gene 
provided by Dr. David Schaffer [24] was loaded into PLGA implants. A luciferase assay 
was performed with the known concentration of AAV standards, and the MOI of 
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extracted and released AAV from the implants was measured. The resulting infectivity of 
extracted AAV from the implants was 116 ± 18 % (mean ± SD, n=3), but it was at the 
basal level for released AAV. Although the infectivity of released AAV was not 
quantified due to the limit of detection, it was confirmed that infectivity of encapsulated 
AAV in PLGA implants was well-preserved. 
 
A.4 Conclusion 
In conclusion, we have successfully encapsulated AAV into PLGA implants for 
controlled release while preserving its infectivity. A preliminary experiment was 
performed to find a proper release buffer for a reliable in vitro release determination and 
it was demonstrated that HBS with 5 mM MgCl2 and 0.02 % Tween 80 provides a proper 
buffer in which more than 85 % of AAV incubated at 37°C can be detected by CEX-
HPLC up to 4 weeks. For sufficient volumetric loading of AAV powder, BSA was co-
encapsulated in PLGA implants. Also, trehalose, and MgCO3 were incorporated in the 
implants to stabalize the encapsulated AAV and BSA. AAV was released continuously 
with near zero-order release kinetics over 3 weeks from the implants and the total 
cumulative release normalized to its extracted loading was 94 %. Luciferase assay 
confirmed that infectivity of AAV encapsulated in the PLGA implants is well-preserved. 
Further work to measure the infectivity of released AAV from the implants is needed, 
along with evaluation for efficacy and advantages of the PLGA implant over free AAV 
injection in animals.   
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Table A.1: Composition in 1 mL of AAV solution and dry weight percentage of each 
component in lyophilized AAV powder. 
Composition Weight (mg) Dry weight percentage (%) 
AAV 0a 0 
BSA 10 25.2 
Trehalose dihydrate 15 37.7 
HEPES 4.77 12.0 
Sodium chloride 8.77 22.1 
Magnesium chloride 1.02 2.6 
Tween 80 0.20 0.5 
a 2.2 × 1013 vg of AAV has negligible weight. 
 
 
Table A.2: Weight percentage of each component in implant. 
Composition Weight percentage (%) 
PLGA (50:50) 82.0 
MgCO3 3.0 
AAV powder 15.0 
(BSA)a (3.8) 
a BSA is a part of AAV powder.  
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Figure A.1: Relative AAV stability in PBS (●) and HBS with 5 mM MgCl2 and 0.02 % 
Tween80 (○) at 37 °C. Data reported as mean ± SD, n=3. 
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Figure A.2: Release kinetics of AAV (A) and BSA (B) from PLGA implants in HBS 
with 5 mM MgCl2 and 0.02 % Tween 80. Data reported as mean ± SD, n=2. 
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Figure SA.1: Representative chromatogram of AAV in CEX-HPLC. AAV peak is in red. 
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Figure SA.2: Standard curve of luciferase assay. 
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